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ABSTRACT 
Marjorie A. Margolis: Provider Communication for HPV Vaccination:  
Geographic Disparities and Response to Parental Declination 
(Under the direction of Melissa B. Gilkey) 
Introduction. Improving provider communication about HPV vaccination is essential to 
increasing uptake among US adolescents. This dissertation sought to: 1) examine geographic 
disparities in HPV vaccination recommendations and coverage, and 2) evaluate provider 
response and follow-up to parental declination of HPV vaccination. 
Methods. Aim 1 and 2 used a national probability sample of 17,251 parents of 13- to 17-year-old 
adolescents. Adolescents resided in 56 immunization jurisdictions (comprised of 50 US states 
and 6 regions) that receive federal grants to finance immunization programs such as Vaccines for 
Children (VFC), a program that delivers free vaccines to eligible children. I used weighted 
multilevel logistic regression to identify jurisdiction characteristics correlated with receipt of a 
provider recommendation and HPV vaccination initiation (≥1 dose). Aim 3 used data from a 
national survey of US parents who reported declining HPV vaccination during their initial 
discussion with a provider (n=447). I used multivariable logistic regression to assess associations 
between provider response during the visit and follow-up after the visit with secondary 
acceptance of HPV vaccination. 
Results. Jurisdiction characteristics explained 4% of the variability in both provider 
recommendations and HPV vaccination initiation. Adolescents less often received a provider 
recommendation if their jurisdiction did not have Medicaid expansion (74% vs. 80%, adjusted 
odd ratio [aOR]:0.77; 95% CI:0.66:0.91) or had higher poverty rates (aOR:0.64; 95% 
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CI:0.48:0.86). Adolescents more often initiated HPV vaccination if their jurisdiction had higher 
proportions of provider recommendations (aOR:1.53; 95% CI:1.28:1.82) and less often initiated 
HPV vaccination if their jurisdiction did not have universal VFC programs (68% vs. 77%, 
aOR:0.79; 95% CI:0.64:0.98). Parents who initially declined HPV vaccination had higher odds 
of secondary acceptance if they received any follow-up after the visit (43% vs. 20%, aOR:3.19; 
95% CI:2.00:5.07).  Secondary acceptance was not associated with an active response during the 
visit.  
Conclusions. An area’s economic environment may contribute to whether an adolescent receives 
a provider recommendation or initiates HPV vaccination. Providers’ follow-up after the visit 
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 CHAPTER ONE: OVERVIEW AND SPECIFIC AIMS 
Human papillomavirus (HPV) vaccination could eliminate most HPV-associated 
cancers,2 but low uptake currently limits the potential of this cancer prevention tool in the United 
States (US).3 The US Advisory Committee on Immunization Practices (ACIP) recommends that 
adolescents receive two doses of HPV vaccine prior to age 13.4 However, only 54% of 
adolescents, age 13-17, were up-to-date by 2019.1 In addition, HPV vaccination is characterized 
by substantial geographic disparities. By 2019, coverage ranged from 31% in Mississippi to 79% 
in Rhode Island.3 Thus, while no US state has met the Healthy People 2030 goal of 80% 
coverage for ages 13-15, some are much farther from that goal than others.  
Many adolescents do not benefit from the most effective intervention to promote HPV 
vaccination: a healthcare provider’s recommendation. Research consistently demonstrates that a 
provider’s recommendation is a strong predictor of HPVvaccination.5-10 Receipt of a high-quality 
recommendation is associated with about nine times the odds of vaccinating.7 A provider’s 
recommendation influences HPV vaccination more strongly than parents’ attitudes and beliefs, 
such as perceived vaccine effectiveness, perceived barriers, and perceived harms, or 
sociodemographic characteristics, such as race/ethnicity and socioeconomic status.5 Despite this 
strong evidence, only 78% of parents of eligible adolescents report receiving a provider 
recommendation.3 This low percentage has led the President’s Cancer Panel to prioritize the goal 
of increasing the frequency and quality of provider recommendations for HPV vaccination.11 In 
addition to making initial recommendations, providers can also play a role in counseling parents 
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who initially decline vaccination to promote secondary acceptance of HPV vaccination and 
reduce the amount of time adolescents are under-immunized.12,13  
The role of provider communication in geographic disparities for HPV vaccination 
remains largely unexplored. The strong geographic disparities in HPV vaccination coverage 
suggest that both individual characteristics (such as age and gender) as well as local or state 
characteristics (such as public health infrastructure) may contribute to an individual’s likelihood 
of HPV vaccination. In addition, some evidence indicates that provider recommendations may 
vary by state.3,14 Given the provider’s outsized role in HPV vaccination, studying whether 
geographic disparities occur for provider recommendations could reveal an underlying 
mechanism that explains geographic disparities in HPV vaccination. In particular, state and 
regional health departments may influence provider recommendations through health policies 
and programs (e.g., quality improvement programs and state immunization financing programs) 
to increase HPV vaccination. For example, participation in Vaccines for Children (VFC), a 
program delivered to Section 317 Immunization Jurisdiction Grantees in 56 state and local areas, 
provides free vaccines for eligible adolescents.15 Variation in VFC may align with disparities in 
HPV vaccination, given that jurisdiction’s VFC program participation varies widely in terms of 
their eligibility requirements for adolescents and providers. Likewise, some evidence indicates 
that Medicaid expansion states may be associated with geographic variation in HPV 
vaccination.16 Such variation could lead to geographic differences in provider recommendations, 
and, in turn, account for differences in HPV vaccination coverage.  
How providers can increase secondary acceptance among parents who initially decline 
HPV vaccination is a second unexplored area. Overall, approximately one-third of parents refuse 
or delay HPV vaccination,13 although many of these parents later vaccinate.12 Little is known 
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about how providers respond to parents who refuse or delay, or how their response may correlate 
with parents’ perceptions and affect during the conversation. A provider response that is more, 
versus less, active may ultimately be more effective at promoting “secondary acceptance” of 
HPV vaccination at a later visit by addressing parental concerns (e.g., vaccine confidence). An 
active response could consist of offering written information or trying to change parents’ minds, 
whereas a less active response could consist of moving on without comment. Likewise, provider 
follow-up after the visit, such as sending a reminder or scheduling another visit to talk about 
vaccination, could cue parents who declined to change their mind. Understanding associations 
between provider response during the visit and follow-up after the visit to HPV vaccination 
declination and parents’ affect and vaccination behavior could inform interventions to help 
providers communicate with parents to promote secondary acceptance of HPV vaccination. 
To address these research gaps, this dissertation assessed geographic disparities in 
provider recommendations and provider response and follow-up to HPV vaccination declination. 
In the first aim, I used provider-verified vaccination data on over 17,000 adolescents from a 
nationally representative sample to identify the jurisdiction- and adolescent-level factors 
associated with patient receipt of a provider recommendation for HPV vaccination in a 
multilevel framework. This framework included novel jurisdiction-level characteristics such as 
health programs and policies (e.g., VFC program type and Medicaid expansion) as potential 
correlates of receiving a provider recommendation. The second aim examined whether provider 
recommendations at the jurisdiction level, conceptualized as the proportion of adolescents 
receiving provider recommendations, are associated with HPV vaccination above and beyond an 
individual’s receipt of a provider recommendation. I also examined the role of jurisdiction health 
programs and policies in HPV vaccination. Because a sizeable minority of parents decline HPV 
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vaccination despite receiving a provider recommendation, my third aim used a separate national 
dataset to examine associations between parents’ report of provider communication and 
secondary acceptance of HPV vaccination. My dissertation aims are to: 
Aim 1. Evaluate associations between jurisdiction health policies and programs and receipt 
of a provider recommendation.  
Activities to address this aim: 
a) examine ICC of provider recommendation in a null multilevel logistic regression model 
to quantify the proportion of total variance in provider recommendations that is attributed 
to jurisdictions.  
b) specify a multilevel logistic regression model in which receipt of a provider 
recommendation is the dependent variable and jurisdiction health policies and programs 
are independent variables to evaluate whether receipt of a provider recommendation is 
more common in jurisdictions with more robust health policies and programs. 
Aim 2. Evaluate associations of jurisdiction-level variables, proportions of provider 
recommendations and health policies and programs, with HPV vaccination initiation. 
Activities to address this aim: 
a) specify a multilevel logistic regression model in which HPV vaccination initiation is the 
dependent variable and jurisdiction health policies and programs and jurisdictions’ 
proportions of provider recommendations are the independent variables, controlling for 
sociodemographic characteristics, to determine: 
b) specify a multilevel structural equation model to examine the extent to which receipt of a 
provider recommendation mediates the relationship between jurisdiction health policies 
and programs, controlling for adolescent characteristics. 
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Aim 3. Establish whether provider response and follow-up to HPV vaccination declination 
are associated with parents’ secondary acceptance. 
Activities to address this aim: 
a) specify a logistic regression model examining the association of two variables, provider 
active response and provider follow-up, with secondary acceptance of HPV vaccination. 
The findings of the proposed research carry the potential to identify modifiable correlates 
of the strong geographic disparities in HPV vaccination coverage and could inform future 
jurisdiction policy or programmatic efforts. This study could also enhance our ability to target 
interventions to geographic areas where they are most needed. Finally, this research can assist 
providers in understanding how to effectively respond to parents who refuse or intentionally 
delay HPV vaccination. A greater understanding of the underlying mechanisms of geographic 
disparities in HPV vaccination coverage as well as provider communication approaches to 
parental declination will lead to actionable findings that can be used to improve HPV vaccination 
coverage and protect adolescents from future HPV cancers. 
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CHAPTER TWO: BACKGROUND AND LITERATURE REVIEW 
Introduction 
HPV-associated cancers represent a substantial public health burden.  HPV is the most 
common sexually transmitted infection in the US, with approximately 79 million estimated 
cases, and 14 million newly acquired infections annually.17 HPV infection is associated with 
about 35,000 cases of cervical, vulvar, vaginal, penile, anal, and mouth and throat cancer.18 Over 
15,000 individuals are diagnosed with oropharyngeal cancer, which are not detected through 
routine screening programs.19 In addition, over 11,000 individuals are diagnosed with cervical 
cancer, and 4,000 die of the disease annually.19 Cervical cancer mortality rates demonstrate racial 
and ethnic disparities; Black and Hispanic women have higher cervical cancer mortality rates 
compared with non-Hispanic White women.19 The high prevalence of HPV infection as well as 
HPV-associated cancers indicates that HPV remains an urgent problem in cancer prevention.   
HPV vaccination could prevent many of these cancers, but uptake remains suboptimal. 
The Advisory Committee on Immunization Practices (ACIP) recommends that all children 
receive two doses of HPV vaccine by ages 11-12 and that children who have not started the HPV 
vaccine series by age 15 receive 3 doses of the vaccine.20 The efficacy of the 9-valent HPV 
vaccine in preventing precancerous lesions associated with the vaccine HPV types is 97%, and 
extensive clinical trials have identified no serious safety concerns associated with delivery of 
HPV vaccine.2 However, only 72% of 13- to 17-year-old adolescents had received one dose of 
the vaccine, and only 54% were up-to-date in 2019.1 This proportion falls far short of the 
Healthy People 2030 goal of having 80% of 13- to 15-year-old adolescents up to date21 and 
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represents a missed opportunity to prevent HPV-associated cancers. For this reason, the Centers 
for Disease Control and Prevention, the American Cancer Society, and the President’s Cancer 
Panel have prioritized the goal of increasing HPV vaccination coverage in the US.11,22,23 
A healthcare provider’s recommendation is the most influential factor with regard to 
HPV vaccination. Adolescents who receive a provider recommendation have odds of initiation 
that are tenfold greater than adolescents who do not.10 Receipt of a provider recommendation is 
more strongly associated with initiation than parental attitudes and beliefs, such as perceived 
efficacy and perceived safety.5 Despite strong evidence of the importance of provider 
recommendations for HPV vaccination, only about 78% of parents report receiving a provider 
recommendation,3 with racial/ethnic minorities and lower-income adolescents less likely to 
report receiving a recommendation.6,24-27 In addition, only a minority of parents (36%) report that 
providers deliver high-quality recommendations for HPV vaccine, by encouraging same day 
vaccination, emphasizing cancer prevention, and strongly endorsing the vaccine.7 Evidence-
based interventions directed at provider recommendations, such as those that teach providers to 
use a presumptive approach of delivering brief statements that assume parents are ready to 
vaccinate, have been effective at increasing HPV vaccination coverage.28 For this reason, 
intervening with providers to improve their HPV vaccine recommendations is a high priority 
initiative. 
Aim 1 and 2: Geographic Disparities in HPV Vaccination 
HPV vaccination is characterized by striking geographic disparities. HPV vaccination 
coverage varies significantly by US Census region (Northeast, Midwest, South, West)25,27 and by 
state (Figure 2.1).1,14,29-31 HPV vaccination completion ranges from 31% in Mississippi to 79% in 
Rhode Island.1 Little is known about why geographic disparities in HPV vaccination coverage 
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exist, with existing 
research identifying 
only weakly 
associated factors. For 
example, one study 
demonstrates that the 
few states with HPV 
vaccination school entry 
requirements or stronger school entry requirements for other adolescent vaccines have small but 
significant increases in HPV vaccination coverage,32 but another study indicates that HPV 
vaccine school entry requirements have no impact.33 In addition, one study demonstrates that the 
proportion of individuals identifying as highly religious and conservative in a state explains a 
small amount of state-level variance in HPV vaccination coverage.29 Living in a Medicaid 
expansion state is associated with higher likelihood of HPV vaccination initiation.16 Finally, 
provider communication style, in terms of whether communication is collaborative versus not, 
may partially explain the higher HPV vaccination coverage in the Northeast US  Census region 
compared to the South.34  
Some research supports geographic variation in provider HPV vaccination 
recommendations by US Census region,27,34-36 and one study demonstrates state-level variation in 
provider recommendations given to male adolescents.14 This ecological study further 
demonstrates that state proportion of provider recommendations is strongly correlated with 
states’ HPV vaccination coverage among males (r=0.80, p<.01) and varies greatly from 46% in 
Wyoming to 83% in Maine. These stark geographic disparities in provider recommendations by 
Figure 2.1. HPV vaccination coverage by state, 20191 
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state suggest that contextual factors of an adolescent’s place of residence influence their 
likelihood of receiving a provider recommendation. However, geographic variation in provider 
recommendations has not been studied in a multilevel context that examines the relative 
contribution of area to an individual’s likelihood of receiving a provider recommendation. Such 
research could be particularly insightful as a potential explanation for the strong geographic 
disparities in HPV vaccination coverage. Thus, my dissertation uses multilevel analysis to 
examine area-level factors that may explain geographic variation in HPV vaccination coverage, 
with a particular focus on provider recommendations as a possible underlying mechanism. 
Overview of the Conceptual Model 
My conceptual model depicts the hypothesized pathways through which area-level 
factors could influence provider recommendations and, ultimately, HPV vaccination coverage 
(Figure 2.2). Area is defined at the level of Section 317 Immunization Jurisdictions, consisting of 
45 US states; the District of Columbia (DC); Chicago, IL; New York City, NY; Houston, TX; 
San Antonio, TX; Philadelphia, PA; and, 4 “rest of state” areas. These immunization 
jurisdictions receive federal grants to delivery and implement vaccination programs. 
This model uses a multilevel framework that examines adolescents within immunization 
jurisdictions and is informed by Andersen’s Behavioral Model of Healthcare Utilization.37 
Andersen’s model conceptualizes use of health services as influenced by both contextual factors 
and individual factors. The model outlines predisposing and enabling characteristics of both 
individuals as well as their context that influence the process of medical care (e.g., patient-
provider communication) and health care use. Predisposing characteristics are existing 
conditions, such as age and gender, that make individuals inclined to use or not use health 
services although they are not directly responsible for health. Enabling characteristics, such as 
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health insurance, facilitate or impede the use of health services. My conceptual model proposes a 
series of predisposing and enabling characteristics at both the individual and contextual level that 
could influence whether a provider recommends HPV vaccination and, in turn, likelihood of 
HPV vaccination. The next section of this chapter describes the following domains of the 
conceptual model: the process of medical care, jurisdiction-level enabling and predisposing 
factors, and adolescent-level enabling and predisposing factors. 
 
Figure 2.2. Conceptual model of geographic disparities in HPV vaccination coverage 
Process of Medical Care 
This conceptual model examines provider recommendations as a process of medical care 
that may contribute to geographic disparities in HPV vaccination. As noted above, some research 
indicates that provider recommendations vary by geography. In addition to the study 
demonstrating jurisdiction disparities in provider recommendations given to male adolescents,14 
several studies demonstrate that the Northeast and Midwest US census regions have higher 
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proportions of provider recommendations than the South.27,34,35 However, these studies are 
limited by either an overly broad geographic range (US Census region), lack of a multilevel 
approach, or restricted (e.g., male only) samples.14,27,34-36 Despite limitations, these studies 
highlight the potential relevance of provider recommendations in a multilevel context that 
examines the extent to which provider recommendations are clustered by jurisdiction. Although 
we know that certain individuals are more likely than others to receive a provider 
recommendation based on individual demographic factors (e.g., gender, income), less is known 
about whether and why individuals living in certain jurisdictions are more likely to receive a 
provider recommendation than others. 
To address this gap, this study will use a large, national dataset of over 17,000 
adolescents in all 56 immunization jurisdictions to examine the extent to which: 1) provider 
recommendations vary between and within jurisdictions; 2) between and within jurisdiction 
variation in provider recommendations correlates with an adolescents’ odds of HPV vaccination; 
and 3) jurisdiction’s health policies and programs are associated with variation in receipt of a 
provider recommendation and HPV vaccination initiation. By examining provider 
recommendations in a multilevel context, I will determine the extent to which adolescents’ 
jurisdiction of residence influences their odds of receiving a provider recommendation. 
Substantial variation in provider recommendations by jurisdiction would indicate that contextual 
factors of the jurisdiction environment may contribute to individual likelihood of receiving a 
provider recommendation.  
Jurisdiction Enabling Characteristics 
In addition to examining the extent to which provider recommendations vary by 
jurisdiction, this dissertation will examine jurisdiction-level enabling characteristics that may 
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contribute to that variation. Jurisdiction health policies and programs can act as jurisdiction-
level, enabling characteristics that help providers to recommend HPV vaccination. The Vaccines 
for Children (VFC) program is a crucial health program in vaccine financing and supply; VFC is 
a federally funded program that offers vaccines at no cost to adolescents who may not otherwise 
be able to pay.15 The VFC program distributes vaccines to state and regional health departments 
who, in turn, supply the vaccine to private physicians’ offices, Federally Qualified Health Care 
Centers (FQHCs), or community-based clinics that are registered as VFC providers.15 VFC 
program participation involves communication, coordination, and training between the state 
health department and the receiving medical organization, which could have a positive 
consequence of encouraging providers to recommend HPV vaccination. In addition, providers 
who participate in the VFC program have lower up-front costs to stock the vaccine, which could 
increase providers’ willingness to recommend it.  
Jurisdiction-level variation in VFC eligibility could help explain jurisdiction-level 
variation in provider recommendations and HPV vaccination coverage. Some jurisdictions have 
VFC program types with more inclusive eligibility requirements for children in offering vaccines 
to all children, while others offer vaccines only to children who are uninsured, underinsured, or 
medically prioritized (e.g., Medicaid-eligible, American Indian/Alaskan Native, uninsured, and 
underinsured). States that offer vaccines to all adolescents (i.e., “universal” VFC) demonstrate a 
10-13% increase in HPV vaccination coverage compared to states without universal coverage.38 
This area-level differences in VFC program type could influence area-level variation in provider 
recommendations.  
Medicaid expansion is a health policy that could also influence geographic variation in 
HPV vaccination coverage. Adolescents in states with Medicaid expansion have a higher 
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likelihood of initiating HPV vaccination.16 These increases could be due to increases in insurance 
coverage after the Patient Protection and Affordable Care Act was implemented. Some of the 
increases in insurance coverage under the Affordable Care Act were attributed to the woodwork 
effect, in which individuals who were previously eligible for Medicaid enrolled in insurance due 
to increased publicity and reduction in administrative barriers. Thus, parents of children may 
have been more likely to enroll in insurance due to Medicaid expansion. Medicaid expansion 
jurisdictions may also offer more healthcare infrastructure that offer more opportunities for 
adolescents to see providers or to receive higher quality care. These differences could explain 
why adolescents in Medicaid expansion jurisdictions are more likely to initiate HPV vaccination. 
Overall, jurisdiction-level variation in VFC programs and Medicaid expansion could lead 
to variation in provider recommendations by jurisdiction. Thus, I hypothesize that adolescents 
have lower odds of receiving a provider recommendation if they live in jurisdictions without 
universal VFC programs (Hypothesis 1a) and if they live in jurisdictions without Medicaid 
expansion (Hypothesis 1b).  
Jurisdiction-level variation in provider recommendations suggests that environment plays 
an important role in whether an adolescent receives a recommendation.  This variation is likely 
to influence an adolescent’s likelihood of HPV vaccination.  This study will examine 
associations between provider recommendations as a multilevel independent variable (which is 
measured between and within jurisdictions) and HPV vaccination initiation as a dependent 
variable to determine the extent to which the proportion of provider recommendations in an 
adolescent’s jurisdiction correlates with their likelihood of HPV vaccination initiation. Because 
provider recommendations are so influential at the individual level and because research 
indicates a correlation between jurisdiction prevalence of provider recommendations and 
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jurisdiction HPV vaccination coverage,14 I expect that adolescents living in jurisdictions with 
higher proportions of provider recommendations have higher odds of HPV vaccination initiation 
(Hypothesis 2a). Jurisdictions’ proportion of provider recommendations could also impact the 
association between an adolescent’s receipt of a provider recommendation and HPV vaccination 
initiation. Living in a jurisdiction with higher proportions of provider recommendations could 
strengthen the association between receiving a provider recommendation and HPV vaccination 
initiation because parents may be more receptive to a provider’s recommendation or because 
providers may be more likely to deliver high-quality recommendations. For this reason, I 
hypothesize that the association between receipt of a provider recommendation and HPV 
vaccination initiation is stronger in jurisdictions with higher, versus lower, proportions of 
provider recommendations (Hypothesis 2b).  
Ultimately, the influence of jurisdiction health programs and policies could explain 
differences in HPV vaccination coverage. Based on prior research,16,38 I hypothesize that 
adolescents have lower odds of HPV vaccination initiation if they live in jurisdictions without 
universal VFC programs (Hypothesis 2c) and jurisdictions without Medicaid expansion 
(Hypothesis 2d). Finally, I hypothesize that universal VFC programs and Medicaid expansion 
increase an adolescent’s odds of HPV vaccination initiation, partially through receipt of a 
provider recommendation (Hypothesis 2e). 
Jurisdiction Predisposing Characteristics 
My conceptual model also includes covariates that have been shown to influence HPV 
vaccination coverage. At the jurisdiction-level, poverty rate and racial/ethnic composition are 
characteristics that could predispose individuals to use or not use health services, although they 
are not directly responsible for use. Jurisdictions’ income or poverty rate could exert an impact 
 
15 
on HPV vaccination that is distinct from an individual’s income or poverty rate. Females living 
in lower income states (conceptualized as states with a higher proportion of the population living 
below poverty) have lower odds of initiation, whereas low-income females have higher odds of 
initiation.31 Similarly, the proportion of racial/ethnic minorities in zip codes is associated with 
HPV vaccination coverage, with zip codes with a high proportion of Hispanic/Latino residents 
having higher HPV vaccination coverage.30 These findings highlight the need for multilevel 
analysis in HPV vaccination research by indicating that variables can exert different effects when 
aggregated to a geographic area (proportion of individuals living in poverty in a jurisdiction) 
versus individual (an individual’s poverty status). Finally, adolescents living in rural areas (non-
metropolitan statistical areas [MSAs] or MSA non-principal cities) have lower HPV vaccination 
coverage than adolescents living in urban areas (MSA principal cities).3 Jurisdictions’ proportion 
of rural residents denotes an important contextual characteristic that could potentially influence 
HPV vaccination through access to care.  
Adolescent Enabling Characteristics 
The conceptual model incorporates health insurance type as an individual-level enabling 
characteristic. Adolescents who are insured have higher HPV vaccination coverage than 
uninsured adolescents.5,25,27,30 Among insured adolescents, adolescents covered through 
Medicaid have higher HPV vaccination coverage than those with private insurance plans.3 The 
differences in coverage by insurance type (Medicaid versus private insurance) could suggest that 
the VFC program is achieving the goal of preventing disparities in HPV vaccination coverage. 
Adolescent Predisposing Characteristics 
Finally, the model includes the following adolescent-level predisposing characteristics 
associated with HPV vaccination as covariates: child age, child gender, child race/ethnicity, 
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maternal education, and income. Older adolescents,3,5 females,3 Hispanic and non-Hispanic 
Black adolescents3,24,39 have higher HPV vaccination coverage compared to their counterparts. In 
addition, adolescents from lower-income households3,24,27,31 and with mothers of lower 
educational attainment (high school degree or less)40 have higher HPV vaccination coverage. 
Higher coverage among traditionally disadvantaged groups (e.g., racial/ethnic minorities) is 
surprising, but consistent across many studies.3,24,27,39,41 Similar to the findings with Medicaid, 
this pattern could be an achievement of VFC and other immunization jurisdiction programmatic  
efforts in addressing disparities in HPV vaccination coverage.39  
Aim 3: Parental Declination of HPV Vaccination 
In addition to understanding how jurisdiction-level context influences whether a provider 
recommends HPV vaccination, a second pressing issue involves how providers can communicate 
with parents who refuse or delay HPV vaccination. Parental refusal and intentional delay of HPV 
vaccination (or “declination”) substantially contributes to suboptimal HPV vaccination coverage. 
Parental declination of HPV vaccination ranges from 30% to 36% in national surveys.13,42 These 
proportions are far higher than for other routine adolescent vaccines, such as tetanus, diphtheria, 
and acellular pertussis (2%) or meningococcal vaccine (5%).43 Developing successful strategies 
to address HPV vaccination declination is critical to achieving the Healthy People 2030 goal of 
having 80% of 13- to 15-year-old adolescents up to date.21 
Several modifiable cognitive and affective factors, such as low vaccine confidence, low 
perceived vaccine efficacy, and high perceived vaccine harms, are associated with parental HPV 
vaccination declination.13 Physicians also report parental moral or religious objections and safety 
concerns about HPV vaccination as barriers to HPV vaccination.44 Physicians report parents’ low 
perceived likelihood of contracting an HPV-related disease and parental discomfort around 
 
17 
discussions of sex as reasons for parental HPV vaccination declination.45 These modifiable 
factors represent targets for future interventions to address and reduce parental HPV vaccination 
declination.  
Among parents who initially decline HPV vaccination, almost half (45%) later decide to 
vaccinate (secondary acceptance), and an additional 24% report that they intend to vaccinate in 
the next 12 months.46  Parents have higher odds of secondary acceptance if they initially receive 
a high-quality HPV vaccination recommendation, if they have greater satisfaction with their 
provider’s communication, and if they have higher vaccine confidence. Receipt of additional 
counseling from a provider is one of the strongest factors associated with secondary acceptance 
of HPV vaccination (OR: 2.16; 95% CI: 1:42:3.28), although only about half of parents (52%) 
report receiving such counseling.46   
Little is known about what specific aspects of counseling can successfully increase 
secondary acceptance among parents who initially decline HPV vaccination. Providers report 
responding to parental HPV vaccination hesitancy (a motivational state of conflict or opposition 
to vaccination47) by offering reassurances of safety, providing written information to parents, and 
by asking questions to probe parents’ concerns,45 but how these actions are associated with 
parents’ HPV vaccination perceptions and behavior is unknown. In particular, associations 
between specific provider response to HPV vaccination declination during the visit and follow-
up after the visit and secondary acceptance have not been studied.  
The Increasing Vaccination Model offers a useful framework to understand how provider 
communication might increase secondary acceptance.47 This model describes two key 
psychological principles that could motivate secondary acceptance: 1) changing thoughts and 
feelings, such as risk appraisals and vaccine confidence; and, 2) direct behavior change, such as 
 
18 
reminders and prompts, that leverage favorable intentions to vaccinate. Thoughts and feelings 
include risk appraisals, such as how likely a person is to get the disease, and anticipated regret, a 
person’s expectation that they will wish they had acted differently in the face of an unpleasant 
outcome.47 Thoughts and feelings are consistently associated with HPV vaccination in 
observational studies, although interventions to change thoughts and feelings have shown little 
impact on HPV vaccination behavior.47 Direct behavior change stands out as the most effective 
and plentiful of these processes for increasing vaccination.47 Direct behavior change focuses on 
building upon peoples’ existing favorable intentions to vaccinate rather than trying to change 
their thoughts and feelings. Leveraging existing favorable intentions could include strategies 
such as reminders to keep vaccination on peoples’ mind and reducing logistical barriers to 
vaccination (e.g., transportation, cost).  
Provider response and follow-up to parental declination may address these psychological 
processes, with providers uniquely positioned to effectively intervene on direct behavior change 
when parents decline HPV vaccination. During the visit, a provider who engages in an active 
response, such as offering counseling or trying to change a parents’ mind, could attempt to 
change negative thoughts or feelings (e.g., low vaccine confidence or low perceived likelihood of 
HPV infection). Providers can also intervene directly on behavior by leveraging existing 
favorable intentions of parents. Among parents who initially decline, direct behavior change 
could be most effective with parents who are hesitant but not completely resistant to vaccination. 
A provider could follow-up after the visit with a reminder that cues parents to keep vaccination 
in mind. By changing thoughts and feelings during the visit or leveraging existing good 
intentions after the visit, providers can increase secondary acceptance through their response and 
follow-up. Thus, I hypothesize that adolescents have higher odds of secondary acceptance if they 
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receive an active response from a provider during the visit (Aim 3a) or provider follow-up after 
the visit (Aim 3b).  
Significance and Implications of Proposed Research 
This research will address two critical, yet understudied areas of provider communication 
for HPV vaccination. The first and second aim will offer new understanding into the high 
jurisdiction-level disparities in HPV vaccination coverage. To date, research has not identified 
contributors to that geographic disparity that could inform jurisdictions’ programmatic 
interventions to improve HPV vaccination delivery and outcome. The proposed analysis could 
identify successful aspects of jurisdiction health policies and programs that increase provider 
recommendations and, ultimately, HPV vaccination coverage. The third aim will offer direction 
for providers, clinics, and health systems to improve quality of care by understanding better how 
to respond and follow-up with parents who decline HPV vaccination. Specifically, this research 
may highlight actions that providers should take or avoid to increase secondary acceptance 
among parents who decline HPV vaccination. These two aims will offer novel data on the 
influence of provider communication on HPV vaccination.  
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CHAPTER THREE: METHODS 
Aims 1 and 2 
Aims 1 and 2 Data Sources 
Data for Aims 1 and 2 came from the National Immunization Survey (NIS)-Teen, the 
Association for Immunization Managers (AIM) survey, and several publicly available data 
sources. 
2018 National Immunization Survey-Teen 
NIS-Teen is a national, annual survey conducted by the National Center for 
Immunization and Respiratory Diseases (NCIRD) and the National Center for Health Statistics 
(NCHS) of the Centers for Disease Control and Prevention (CDC) that obtains national estimates 
of vaccination coverage of adolescents ages 13-17 years.48 NIS-Teen estimates vaccination 
coverage using a two-step approach that consists of: 1) a computer-assisted telephone interview 
(CATI) household interview with a parent or guardian of an adolescent ages 13-17; and, 2) a 
mailed questionnaire to the adolescent’s providers to report vaccination coverage based on the 
adolescent’s medical record. In the first step of data collection, NIS-Teen uses random-digit 
dialing (RDD) cellular telephone numbers in the US, including the District of Columbia and US 
territories.48  NIS-Teen provides vaccination estimates for the 56 state and local immunization 
program grantees, consisting of: 45 US states; the District of Columbia (DC); Chicago, IL; New 
York City, NY; Houston, TX; San Antonio, TX; Philadelphia, PA; and, 5 “rest of state” areas.  
The household interview gathers information on an adolescent’s sociodemographic 
information, vaccination history, and health insurance status.49 At the conclusion of the 
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household interview, NIS-Teen obtains contact information of the adolescent’s provider(s) and 
parental or guardian consent to contact the provider. NIS-Teen then mails the provider(s) an 
Immunization History Questionnaire (IHQ) that requests vaccination history from the 
adolescent’s medical record.50 National vaccination estimates are obtained from provider-
verified reports of vaccination.  
NIS-Teen uses separate sampling weights for each phase (RDD and provider-
verification) of data collection.48 Sampling weights represent the approximate number of 
adolescents that one adolescent in the sample represents, adjusted for non-response as well as 
age, gender, race, and ethnicity classes based on population estimates produced by the US 
Census Bureau. NIS-Teen also imputes missing values for socioeconomic, demographic, and 
health insurance information for all adolescents with provider-verified immunization records.48 
In 2018, a sample of 15.5 million mobile telephone yielded 39,268 household 
interviews.48 The response rate, defined by the Council of American Survey Research 
Organizations (CASRO) and equivalent to Response Rate 3 of American Association for Public 
Opinion Research (AAPOR) Standard Definitions, for the household interviews was 26%. Of the 
39,268 household interviews, NIS-Teen obtained provider-verified reports for 18,700 
adolescents (49%).48 Geographic variation in the proportion of provider-verified reports obtained 
ranged from 39% in City of Houston, TX to 60% in Vermont. This dissertation used data from 
the 17,251 adolescents aged 13–17 years with provider-verified vaccination reports and complete 
data on whether they received a provider recommendation. 
Association for Immunization Managers (AIM) Annual Report 
The Association for Immunization Managers (AIM) survey collects data from all state, 
local, and territorial immunization programs that are offered Section 317 Immunization Grants.51 
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Most immunization programs cover the entire state and a small proportion (n=6) cover local 
cities or counties. In 2017, 97% (62/64) of immunization programs responded to the AIM 
survey. The immunization program manager typically completes the AIM survey by providing 
information on immunization programs’ staffing, funding, and immunization promotion, 
coordination, and monitoring efforts. For this dissertation, AIM provided information on each 
immunization program’s participation in the Vaccines for Children (VFC) program. 
Additional Data Sources 
Additional variables came from publicly available sources from the US Census Bureau, 
the Centers for Disease Control and Prevention (CDC), and the Kaiser Family Foundation. The 
US Census is a decennial census that collects data from all United States citizens on their gender, 
age, ethnicity, and race. This dissertation used data from the 2010 US Census to obtain estimates 
of the racial/ethnic composition and poverty rate of each state.52 The Kaiser Family Foundation 
provided information on which states have implemented Medicaid expansion as of 2018.53 
Finally, the CDC provided the number of individuals living in non-metropolitan statistical areas 
(MSA).54  
Aims 1 and 2 Measures 
The primary dependent variables for Aims 1 and 2, respectively, were: 
Provider recommendation for HPV vaccination. NIS-Teen’s household survey asked 
parents whether “a doctor or other health care professional ever recommended that [TEEN’S 
NAME] receive HPV shots”. I coded parents as: 0 (“no,”) versus 1 (“yes”).  
HPV vaccination initiation. I used NIS-Teen’s Immunization History Questionnaire 
(IHQ), which gave a provider-verified report of the number of doses of HPV vaccine the 
adolescent received. I coded adolescents with at least one dose of HPV vaccine as having 
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initiated HPV vaccination. HPV vaccination initiation was used as a primary outcome variable 
because it is a prerequisite to HPV vaccination completion and most adolescents who initiate 
complete the series.3   
My jurisdiction-level independent variables were: 
Vaccines for Children (VFC) program type. Jurisdictions’ VFC eligibility describes how 
many adolescents are eligible to receive vaccines through the VFC program. Each jurisdiction 
chooses the specific vaccines they supply as well as adolescents’ eligibility to receive HPV 
vaccine. Jurisdictions’ level of participation, or program type, extends from universal coverage 
(supplying all recommended vaccines for all adolescents); universal-select (supplying all but a 
few recommended vaccines for all adolescents); VFC & underinsured (supplying all 
recommended vaccines for any adolescent who is uninsured, underinsured, or medically 
prioritized (e.g., Medicaid-eligible, American Indian/Alaskan Native); and, VFC-only (supplying 
all recommended vaccines for any adolescent who is uninsured, Medicaid-eligible, or American 
Indian/Alaskan Native). Because of the small number of underinsured adolescents, I combined 
VFC and VFC & underinsured. Thus, I coded jurisdictions according to whether their eligibility 
is: 1) VFC-eligible and underinsured adolescents or universal-select vs. 0) universal VFC 
program. 
Medicaid Expansion. Under the Affordable Care Act, some states expanded Medicaid 
programs to cover all people under age 65 with household incomes up to 138 percent of the 
federal poverty level. I coded each jurisdiction as having not having implemented Medicaid 
Expansion (1) or having implemented Medicaid expansion (0), as of January 2018. 
Additional covariates for Aim 1 and 2 are listed in Appendix A, Table A.1. 
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Aim 1 Analysis Plan 
Hypothesis 1a: Adolescents have lower odds of receiving a provider recommendation if 
they live in jurisdictions without universal VFC programs. 
Hypothesis 1b: Adolescents have lower odds of receiving a provider recommendation if 
they live in jurisdictions without Medicaid expansion. 
I used multilevel logistic regression to examine: 1) variation in receipt of a provider 
recommendation by jurisdiction; and 2) the association between jurisdiction and adolescent 
characteristics and receipt of a provider recommendation for HPV vaccination. Given the binary 
nature of the outcome variable, logistic regression was an appropriate statistical technique that 
used the logit transformation to convert the probability of the event occurring into a linear 
transformation suitable for regression.55 Multilevel logistic regression was an appropriate 
statistical technique to use because data were clustered such that individuals in the same cluster 
(e.g., jurisdiction) shared related values on an outcome variable. Accounting for this 
interdependence was necessary to obtain correct regression coefficients and unbiased standard 
errors. A multilevel logistic regression model also allowed for examination of the extent to 
which the probability of receipt of a provider recommendation depended on an adolescent’s 
jurisdiction of residence.55 First, I obtained the intra-class correlation (ICC) of receipt of a 
provider recommendation to determine the proportion of total variance in receipt of a provider 
recommendation that was explained by differences between jurisdiction (level 2). This variance 
described the extent to which adolescents (level 1) varied within jurisdictions (level 2) on the 
outcome variable. Because a multilevel logistic regression model does not include level-1 
residuals (within jurisdiction), the assumed level 1 variance was automatically set at 𝜋 /3, the 
variance of the logistic distribution.56 To obtain the ICC, I ran a null multilevel logistic 
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regression model that specified receipt of a provider recommendation as the outcome variable 
and jurisdiction as the cluster-level variable. The null model did not contain any independent 
variables. An ICC greater than zero and significant between jurisdiction variation (τ00) indicated 
that observations were not independent and multilevel modeling was an appropriate statistical 
technique.55,56  
Next, I added in jurisdiction-level variables (VFC program type, Medicaid expansion, 
poverty rate, proportion of Black residents, proportion of Hispanic residents, and proportion of 
rural residents) as well as adolescent-level variables (health insurance type, any VFC provider, 
recent doctors’ visit, age, gender, race/ethnicity, maternal education, and income-to-poverty 
ratio) (Figure 3.1). I examined the univariate distribution of continuous and count variables to 
ensure normality. Adolescent and jurisdiction-level variables were centered based on the 
substantive research question of interest.57 Because income and race/ethnicity variables were 
measured at both the jurisdiction (poverty rate, proportion of Hispanic residents, and the 
proportion of Black residents) and adolescent-level (income, Hispanic ethnicity, and Black race), 
I group mean centered the adolescent variables and included the jurisdiction-level mean in the 
model. This allowed for estimation of the effect of adolescent-level income and race/ethnicity as 
well as jurisdiction-level income and racial/ethnic composition. Continuous or proportional 
jurisdiction-level variables (proportion of Hispanic residents, proportion of Black residents, 
poverty rate, proportion of rural residents) were grand mean centered by subtracting the overall 
mean from each jurisdiction’s mean score. Grand mean centering allowed for interpretation of 
the intercept as the adjusted odds of provider recommendations at the mean of these variables.57 
Dichotomous jurisdiction-level variables (VFC program type, Medicaid expansion) were not 
centered to interpret the intercept as the adjusted mean odds of provider recommendation when 
 
26 
the dichotomous variable was zero. I applied weights to ensure the results were nationally 
representative. Analysis was conducted in SAS version 9.4, and statistical tests were two-tailed 
with a critical alpha of 0.05. 
To test my hypotheses, I examined whether the association between VFC program type 
(non-Universal VFC program) and provider recommendation was significant and negative and 
whether the association between Medicaid expansion status (non-Medicaid expansion) and 
provider recommendation was significant and negative. 
 
Figure 3.1. Analytical pathways, aim 1, hypothesis 1a-b 
Aim 2 Analysis Plan 
Hypothesis 2a: Adolescents living in jurisdictions with higher proportions of provider 
recommendations have higher odds of HPV vaccination initiation. 
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I examined associations between receipt of a provider recommendation at the adolescent-
level (whether an adolescent received a provider recommendation) and jurisdiction-level (the 
proportion of adolescents who received a provider recommendation) and HPV vaccination 
initiation (Figure 3.2). I first ran a null multilevel logistic regression model to obtain the intra-
class correlation (ICC) of HPV vaccination to determine the proportion of total variance in HPV 
vaccination initiation explained by differences between jurisdictions (level 2). Then, I ran a 
multilevel logistic regression model with HPV vaccination initiation as the dependent variable 
and receipt of a provider recommendation at both the adolescent- and jurisdiction-level as the 
independent variable. I added in jurisdiction-level variables (VFC program type, Medicaid 
expansion, poverty rate, proportion of Black residents, proportion of Hispanic residents, and 
proportion of rural residents) as well as adolescent-level variables (health insurance type, any 
VFC provider, recent doctors’ visit, age, gender, race/ethnicity, maternal education, and income-
to-poverty ratio). Variables were centered in the same manner as Aim 1. I examined whether 
provider recommendations at the jurisdiction-level and at the adolescent-level were significantly 
associated with HPV vaccination initiation. I also examined the magnitude of the association 
between jurisdiction-level provider recommendations and HPV vaccination initiation to 
determine how strongly provider recommendations at level 2 (the proportion of adolescents 
receiving a provider recommendation per jurisdiction) correlated with odds of HPV vaccination 
initiation. 
Hypothesis 2b: The association between receipt of a provider recommendation and HPV 




To test this hypothesis, I examined the random slope of an individual’s receipt of a 
provider recommendation. A significant random slope indicated that the effect of an adolescent-
level variable on receipt of a provider recommendation varied by jurisdiction. For example, the 
effect of an adolescent’s income on receipt of a provider recommendation could vary by 
jurisdiction (e.g., income exerts a stronger effect in one jurisdiction compared to another). Since 
the random slope was significant, I added a cross-level interaction examining whether 
jurisdiction’s proportion of provider recommendations interacted with an individuals’ receipt of 
a provider recommendation.  Since the interaction was significant, I probed the interaction to 
determine the direction and magnitude of effects of the association between individual receipt of 
a provider recommendation and HPV vaccination at different values of the moderator, 
jurisdictional proportion of provider recommendations. 
Hypothesis 2c: Adolescents have lower odds of HPV vaccination initiation if they live in 
jurisdictions without universal VFC programs. 
Hypothesis 2d: Adolescents have lower odds of HPV vaccination initiation if they live in 
jurisdictions without Medicaid expansion.  
To test hypothesis 2c and 2d, I examined whether the significance and direction of the 
association between VFC program type (non-universal VFC program) and HPV vaccination 
initiation and Medicaid expansion status (non-Medicaid expansion) and HPV vaccination 




Figure 3.2. Analytic pathways, aim 2a-d 
Hypothesis 2e: Receipt of a provider recommendation partially mediates the association 
between universal VFC program and Medicaid expansion and an adolescent’s odds of HPV 
vaccination initiation. 
To examine this hypothesis, I used a multilevel structural equation model (SEM) that 
examined indirect and direct effects while accounting for clustered data structure. SEM offers 
distinct advantages over traditional multilevel regression models in that multilevel SEM allows 
for simultaneous estimation of all pathways in an equation while also examining between and 
within cluster effects.58 Thus, multilevel SEM can estimate models in which variables 
simultaneously act as predictor and predicted variables.58,59  
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This model examined whether receipt of a provider recommendation mediated 
associations between adolescent-level variables (health insurance type, any VFC provider, recent 
doctors’ visit, age, gender, race/ethnicity, maternal education, income-to-poverty ratio) and 
jurisdiction-level variables (proportion of provider recommendations, VFC program type, 
Medicaid expansion, poverty rate, the proportion of Black residents, the proportion of Hispanic 
residents, and the proportion of rural residents) and HPV vaccination initiation (Figure 3.3). 
After adding variables to the model, I specified the directional and non-directional relationships 
among variables. To obtain absolute fit statistics, I first ran the model using robust weighted least 
squares (WLS).60 I evaluated whether the a priori model adequately fit the sample data using the 
following criteria for each absolute fit statistic: Root Mean Square Error of Approximation 
(RMSEA) less than 0.08;61,62 Standardized Root Mean Square Residual (SRMR) less than 
0.08;63,64 and, Bentler Comparative Fit Index (CFI) greater than 0.95.65 Because the model failed 
to meet these criteria, I respecified the model by removing variables.58,66 If the model had failed 
to converge or display poor fit after respecification, I planned to analyze these mediational 
pathways using a series of multilevel logistic regression models. 
After model specification, I ran the model using marginal maximum likelihood 
estimation with adaptive quadrature numerical integration, which was the estimation technique 
most suited to produce unbiased parameter estimates for a random component models with a 
binary outcome variable, large cluster size, and ICC.67 Although robust WLS is the only 
estimation technique that provides absolute fit statistics for binary dependent variables, it is most 
appropriate when the binary dependent variable represents a threshold of an underlying 
continuous, normally distributed latent variable and contains no clustering.60 In contrast, 
marginal maximum likelihood estimation fits the probability model directly to observed outcome 
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values using a raw-data likelihood function and requires no assumption of an underlying 
continuous latent variable.67  
I examined the extent to which the model decomposed the total effects of exogenous 
variables (variables that are not caused by other variables) on endogenous variables (variables 
that are caused by other variables) into direct and indirect effects. To test the indirect effects, I 
used bootstrapping, in which the model was repeatedly fit to multiple random draws from the 
original sample, to obtain 95% confidence intervals.68 To test this hypothesis, I examined the 





Figure 3.3. Analytic pathways, aim 2e  





Observations used for aim 1 and 2 consisted of 17,251 adolescents and 56 geographic 
units (average cluster size of 274).  For Aim 1, I used the estimated proportion of provider 
recommendations delivered to males (0.66).14 For Aim 2, I used the proportion of US 
adolescents who had initiated HPV vaccination in 2018 (0.68).3 With a criteria alpha of 0.05, 
both analyses had 80% power to detect a difference in proportion of 10% in outcome variables 
(receipt of a provider recommendation and HPV vaccination initiation). For Hypothesis 2e, I 
used the MacCallum et al. approach to determine that I had ample statistical power to obtain a 
model with adequate model fit (RMSEA<0.08).69 With a sample size of 17,251 adolescents and 
15 degrees of freedom, I had >99% power for a well-specified path model.  
Aim 3 
Aim 3 Data Source  
Data from this study come from an online, cross-sectional survey of US parents of 
adolescents conducted from November 2017 to January 2018. Study participants were members 
of an existing, national panel of non-institutionalized adults maintained by a survey company. 
The panel consisted of a probability-based sample of US households constructed using address-
based sampling frames. The survey company used a delivery sequence file of the United States 
Postal Service, covering approximately 97% of the United States. Non-internet households were 
provided with a netbook and internet service. Eligible parents had at least one 9- to 17-year-old 
child who either had not initiated the HPV vaccine series or had received only the first dose. This 
survey focused on parents of children who were not fully vaccinated because they are a high 
priority for vaccine promotion efforts. Parents with more than one eligible child answered survey 
items about the child with the most recent birthday.  
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Of 2,857 parents from the panel who were randomly invited to participate, 1,834 parents 
accessed the screener to confirm having an age-eligible child with 0-1 dose of HPV vaccine. Of 
these parents, 1,313 (72%) met eligibility criteria, provided informed consent, and completed 
some portion of the survey. After we excluded 50 panelists who did not complete at least two-
thirds of the survey, the sample for the survey consisted of 1,263 parents. The response rate was 
61%, using American Association for Public Research Response Rate 4 calculation.70 The 
analytic sample for this study consisted of 447 parents who reported refusing or delaying HPV 
vaccination after having a discussion with their child’s provider about HPV vaccine. The 
Institutional Review Board at the University of North Carolina at Chapel Hill approved the study 
protocol. 
Aim 3 Measures 
The primary dependent variable was: 
Secondary acceptance. Among those who initially declined HPV vaccination, I coded 
those who reported at the time of the survey that their child had received at least 1 dose as having 
achieved secondary acceptance of HPV vaccination. I measured the number of doses of HPV 
using the question, “How many shots of the HPV vaccine has [NAME] had?” 
My primary independent variables were: 
Provider active response.  The survey measured whether a provider actively responded to 
parents who declined HPV vaccination by asking about follow-up actions that providers took 
after the parent initially declined. I coded parents who received an active response from their 
provider as those who reported their provider did one or more of the following: “give more 
information”, “offer to talk about the HPV vaccine again at a later visit”, “try to change your 
mind”, or “ask you to sign a form confirming that you refuse to vaccinate.” Those who did not 
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receive an active response from their provider are those whose provider only did one or more of 
the following: “accept your decision”, “move on with the visit without much comment”, or 
“none of the above”. 
Provider follow-up after the visit.  The survey measured whether a provider followed-up 
after the visit by: “scheduling another visit to talk about it again”, “bringing it up again at the 
next check-up”, or “sending a reminder (phone, text, email or mail)”. I coded those who received 
any follow-up versus those who received none of these.   
Parents’ negative decisional affect. The survey measured parents’ negative decisional 
affect during the visit using a single item, “At that visit, how did you feel about your HPV 
vaccine decision?” Parents reported that they felt one or more of the following: worried, unsure, 
annoyed, uncomfortable, at ease, confident, relieved, optimistic, or none of these. I compared 
parents who reported any negative emotion (annoyed, worried, uncomfortable or unsure) to those 
who did not report any negative emotion.  
Parents’ discomfort with the visit. The survey measured parents’ discomfort with the visit 
using one item, “How did your conversation about the HPV vaccine affect that visit with 
[NAME]’s doctor or health care provider?” The response option consisted of a five-level ordinal 
scale from “much less comfortable” (5) to “much more comfortable” (1).  
Additional covariates are listed in Appendix A, Table A.2. 
Aim 3 Analysis Plan 
Missing data ranged from 0-2% for all variables.  Because standard techniques (listwise 
deletion, mean imputation) can lead to biased parameter estimates and invalid statistical 
inferences, I employed full information maximum likelihood (FIML) to address missing data. 
FIML partitions the dataset into subsets, which are then used to derive parameter estimates.71 I 
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will then examine whether parents who received an active response or follow-up differed from 
those who did not by running logistic regression models that examines associations between 
sociodemographic variables (child’s sex at birth, child’s age, parent’s education, race/ethnicity, 
and annual household income) and provider active response and provider follow-up.  
I specified a multivariable logistic regression model assessing secondary acceptance as 
the dependent variable and provider active response during the visit and provider follow-up after 
the visit as the independent variables (see Figure 3.4). The model will also include demographic 
variables that correlate with HPV vaccination: provider recommendation for HPV vaccination, 
child’s sex at birth, child’s age, parent’s education, race/ethnicity, and annual household 
income.3,8,42,72,73 Conducted in SAS version 9.4, statistical tests were two-tailed with a critical α 
of 0.05. 
After model specification, I examined and interpreted each path of the model as indicated 
below. 
Hypothesis 3a. Adolescents have higher odds of secondary acceptance if they receive 
active response from a provider during the visit. 
Hypothesis 3b. Adolescents have higher odds of secondary acceptance if they receive 
provider follow-up after the visit. 
To test these hypotheses, I examined whether the association between provider active 
response and secondary acceptance was significant and positive and whether the association 
between provider follow-up after the visit and secondary acceptance was significant and positive. 
I conducted sensitivity analysis by examining parents who delayed HPV vaccination and 
parents who refused HPV vaccination separately to see if results changed. I also removed the 
variable “unsure” from negative decisional affect as that emotion could be less negative than 
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others (e.g., annoyed, confused, worried). Finally, I tested whether associations differed between 
whether a provider tried to change a parent’s mind versus all other provider actions. Trying to 
change a parent’s mind was a stronger action that could be more effective than other actions 
(e.g., giving more information or offering to talk at a later visit). If the direction and significance 
of findings changed based on sensitivity analysis, I had planned to report those results separately. 
 
Figure 3.4. Analytic pathways, aim 3a-b 
Power Calculation 
We used the proportion of parents who reported secondary acceptance among a sample of 
parents who declined HPV vaccination from a prior study (0.45).12 My sample size was 447 
adolescents with 11 degrees of freedom. With a criteria alpha of 0.05, I had 80% power to detect 




CHAPTER FOUR. EXAMINING GEOGRAPHIC DISPARITIES IN PROVIDER 
RECOMMENDATIONS FOR HPV VACCINATION (AIM 1) 
Introduction 
Human papillomavirus (HPV) is a highly-prevalent sexually transmitted infection 
associated with about 35,000 cases of cancer in the US each year.18,74 To reduce the high burden 
of HPV-related disease, the Advisory Committee on Immunization Practices (ACIP) 
recommends that all children receive the multi-dose HPV vaccine series at ages 11-12.20 
However, only 54% of adolescents, ages 13-17, were up to date with HPV vaccination in 2019.1 
This level of vaccine coverage falls far short of the Healthy People 2030 goal of having 80% of 
13- to 15-year-old adolescents up to date21 and represents a missed opportunity to prevent HPV-
associated cancers. 
Provider recommendations are the most consistent and strongest predictor of HPV 
vaccination. Adolescents who receive a provider recommendation have odds of initiation that are 
5-18 times greater than adolescents who do not.5,6,8,27 However, only 78% of parents report 
receiving a recommendation and often at a much later age than the ACIP guidelines, which 
recommend HPV vaccination at ages 11-12.3 In addition, certain subgroups of adolescents, such 
as racial/ethnic minorities and those from lower-income households, are less likely to receive a 
recommendation compared to majority group and higher income peers.6,24-27  
In addition to provider and patient factors, geographic factors may also explain whether 
an adolescent receives an HPV vaccine recommendation.14 Health policies and programs, such as 
Medicaid expansion and the Vaccines for Children (VFC) program, are salient geographic 
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characteristics that may impact whether providers recommend HPV vaccination. The VFC 
program is a federally funded program delivered to immunization jurisdictions, state or local 
areas that receive federal grants to finance immunization programs, that provides vaccines at no 
cost to adolescents who may not otherwise be able to pay. Immunization jurisdictions 
(‘jurisdictions’) with ‘universal’ VFC programs that offer vaccines to all adolescents have HPV 
vaccination coverage that is 10-13% higher than states that only offer vaccines to adolescents 
meeting certain socioeconomic or insurance status criteria.38 The VFC program may also make it 
easier for providers to give HPV vaccine by reducing up-front costs to stock the vaccine and 
offering provider education and training to consistently recommend HPV vaccination to all 
adolescents.75,76 Likewise, preliminary studies suggest that adolescents living in states that have 
chosen to expand Medicaid eligibility to those up to 138% of the poverty level have higher odds 
of HPV vaccination.16 This increased access to healthcare by low income adolescent patients 
may lead to an increase in healthcare utilization, offering more opportunities to receive a 
provider recommendation.  
No published studies have examined whether jurisdictions’ VFC program and Medicaid 
expansion are associated with receipt of a provider recommendation, although they are 
associated with greater HPV vaccination coverage. Identifying whether jurisdiction programs 
and policies are associated with receipt of a provider recommendation could uncover an 
underlying mechanism through which these programs influence HPV vaccination. To address 
this gap, we used multilevel modeling (MLM) to analyze a nationally representative dataset 
examining associations between adolescent (level 1) and jurisdiction (level 2) characteristics and 
provider recommendation for HPV vaccination. To the best of our knowledge, this study is the 
first to examine adolescent and jurisdiction characteristics associated with receipt of a provider 
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recommendation in a multilevel context. Thus, this study seeks to add to the literature by 
highlighting jurisdiction policy or programmatic characteristics that are associated with both 
provider recommendations and HPV vaccination.  
Methods 
Data Sources and Sample 
This study used data from the US National Immunization Survey (NIS)-Teen, the 
Association for Immunization Managers (AIM) survey, and several other publicly available 
datasets. NIS-Teen is a national, annual survey conducted by the Centers for Disease Control and 
Prevention (CDC) to estimate national vaccination coverage among adolescents ages 13-17 
years.48 NIS-Teen data collection occurs in two phases: 1) a computer-assisted telephone 
household interview with a parent or guardian of an adolescent ages 13-17 collects data on the 
adolescent’s sociodemographics and health insurance status; and, 2) a mailed questionnaire to 
the adolescent’s providers to ascertain vaccination status based on the adolescent’s medical 
record and to determine whether the provider orders vaccines from the Vaccines for Children 
(VFC) program. NIS-Teen uses separate sampling weights for each phase (telephone interview 
and provider questionnaire) of data collection.48 Sampling weights represent the approximate 
number of adolescents that one adolescent in the sample represents, adjusted for non-response as 
well as age, gender, race, and ethnicity based on population estimates produced by the US 
Census Bureau. NIS-teen uses provider-verified reports of vaccination to derive national 
vaccination coverage estimates.  
In 2018, NIS-teen used a single-frame cellphone random digit dialing (RDD) sampling 
strategy. A sample of 15.5 million telephone numbers yielded 38,706 household interviews 
(American Association for Public Opinion Research RR3: 26%).48,70 Of those household 
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interviews, NIS-Teen subsequently obtained provider-verified reports for 18,700 adolescents 
(49%).48 We excluded those without complete data (i.e.., those who responded don’t know, 
refused, or who had missing response) on our outcome (n=1,449) to obtain our final sample 
consisted of 17,251 adolescents.  
The Association for Immunization Managers (AIM) is a nonprofit organization that 
supports immunization programs receiving funding from the CDC’s Public Health Service 
Section 317 Immunization Grants Program.51 AIM administers an annual survey to program 
managers of immunization programs to collect data on the activities, staffing, and needs of each 
program. The 2017 AIM survey collected data from grantees on each immunization program’s 
participation in the VFC program.51 This study used data from the Section 317 Immunization 
Grantee jurisdictions in the domestic US (n=56). These immunization jurisdictions consist of 6 
regional areas (Washington, DC; Houston, TX; San Antonio, TX; Philadelphia, PA; New York 
City, NY; and Chicago, IL), 4 “rest of state” areas (Texas, Pennsylvania, New York, and 
Illinois), and 46 full states. 
We used several publicly available data sources to gather additional information on 
immunization jurisdictions for use in the analyses. The 2010 US Census reported data on the 
racial and ethnic composition for each immunization jurisdiction and poverty rate. The Kaiser 
Family Foundation provided information on which states have implemented Medicaid expansion 
as of 2018.53 The National Center for Health Statistics provided information on the proportion of 
individuals living in rural areas [defined as non-metropolitan statistical areas (MSA)].54 
Conceptual Framework and Measures 
Our conceptual framework is guided by Andersen’s Behavioral Model of Healthcare 
Utilization.37 Andersen’s model conceptualizes use of health services as influenced by both 
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contextual and individual factors. We conceptualize context at the level of immunization 
jurisdiction, state or local areas that receive federal grants to finance immunization programs, 
such as the Vaccines for Children (VFC) program.77 Jurisdictions vary in the extent to which 
they reach adolescents and this variation could contribute to geographic variation in HPV 
vaccination. The model outlines predisposing and enabling characteristics of both individuals as 
well as jurisdictions that influence the process of medical care (e.g., providers delivering 
recommendations) and health care use (e.g., HPV vaccination). Predisposing characteristics 
make individuals inclined to use health services, while enabling characteristics facilitate or 
impede the use of health services.  
Provider recommendations. Our outcome variable, provider recommendation for HPV 
vaccination, is a process of medical care that may contribute to geographic disparities in HPV 
vaccination. Provider recommendation was assessed with a single NIS-Teen’s household survey 
item that asked parents whether “a doctor or other health care professional ever recommended 
that [TEEN’S NAME] receive HPV shots”. NIS-Teen coded responses as: 0 (“no,”) versus 1 
(“yes”).  
This study will examine the following jurisdiction characteristics that act as enabling 
factors: VFC program type38 and Medicaid expansion.16 
VFC program type. Immunization jurisdictions’ VFC programs have different criteria for 
determining which adolescents are served and which vaccines are distributed through the VFC 
program. Nationally, adolescents are eligible for free VFC vaccines if they meet one of the 
following criteria: 1) uninsured or underinsured; 2) American Indian or Alaskan Native; 3) 
Medicaid-eligible. In addition, some immunization jurisdictions have expanded the VFC 
program to cover additional adolescents. The most expansive type of VFC eligibility is 
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“universal,” such that all adolescents are eligible to receive all ACIP-recommended vaccines 
through the VFC program, regardless of their insurance status or ability to pay. Other types of 
eligibility include distributing: 1) select vaccines to adolescents meeting VFC criteria (VFC-
select); 2) all vaccines to adolescents meeting VFC criteria (VFC-only); and, 3) select vaccines 
to all adolescents (universal-select).15 We assessed immunization jurisdictions’ VFC eligibility 
as whether their eligibility is universal or other (VFC-select, VFC-only, and universal-select). 
Medicaid expansion. Under the Affordable Care Act, some states expanded Medicaid 
programs to cover all people under age 65 with household incomes up to 138 percent of the 
federal poverty level. We coded each jurisdiction as having implemented Medicaid expansion (0) 
or not having implemented Medicaid Expansion (1) as of January 2018. 
This study will examine the following characteristics shown to be predisposing 
characteristics of jurisdictions that are associated with HPV vaccination: proportion of Hispanic 
residents,30,78,79 proportion of Black residents,30,78,79 poverty rate,30,41,78-80 and proportion of rural 
residents.3,30,78-81 Details on how each variable were coded are below. 
Proportion of Hispanic residents. We assessed each jurisdiction’s proportion of Hispanic 
residents as the number of Hispanic residents in an immunization jurisdiction divided by the total 
number of residents in that immunization jurisdiction, as estimated by the 2010 US Census. 
Proportion of Black residents. We assessed each jurisdiction’s proportion of Black 
residents as the number of Black residents in an immunization jurisdiction divided by the total 
number of residents in that immunization jurisdiction, as estimated by the 2010 US Census. 
 Poverty rate. Jurisdictions’ poverty rate consisted of the number of residents with 
incomes below the Federal poverty level divided by the total number of residents in each 
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jurisdiction, as estimated by the 2010 US Census. We then divided this value by 10 so that one 
unit of change in a MLM would correspond to a 10% change in poverty rate. 
Proportion of rural residents. We assessed each jurisdiction’s proportion of rural 
residents as the number of residents who lived in non-metropolitan statistical areas (MSAs), as 
estimated by the National Center for Health Statistics. MSAs are defined as areas with at least 
50,000 residents that have an urban nucleus of at least 1,000 persons per square mile together 
with adjoining territory of at least 500 persons per square mile.54 
Based on prior literature, we added the following adolescent predisposing characteristics: 
age,35,82 gender,25,35,83,84 maternal education (some college or less vs. college degree or more),26 
household income-to-poverty ratio (adolescent’s household income divided by the applicable 
Federal poverty income),25,35,39,83,84 and race/ethnicity (Hispanic, Non-Hispanic Black, Non-
Hispanic White, Non-Hispanic Other/Multiple Race).6,25-27,39,81,82,84-86  
Based on prior literature, we added the following as enabling adolescent characteristics: 
insurance type,27,83 whether the adolescent saw a VFC provider,82,87 and whether the adolescent 
had a recent doctors’ visit.27 
NIS-teen imputed missing values using sequential hot-deck method in which missing 
values are replaced with observed values from similar respondents.48 
Data Analysis 
We first computed weighted descriptive statistics (e.g., mean, percentages) on all 
variables. We then used a weighted multilevel logistic regression model that nested adolescents 
(level 1) within immunization jurisdictions (level 2), with the intercepts treated as random. In 
accordance with best practice recommendations,88 we rescaled provider-confirmed sampling 
weights that account for selection and non-response probability to fit the nested structure of the 
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data. We then tested a series of models using PROC GLIMMIX with maximum likelihood 
estimation with adaptive quadrature. We first obtained the intraclass correlation (ICC) of receipt 
of a provider recommendation clustered by immunization jurisdiction. The ICC represents the 
proportion of total variance for receipt of a provider recommendation that is explained by 
differences between immunization jurisdictions. Because our binary outcome does not include 
within-jurisdiction residuals, per common practice,56 we automatically set the within-jurisdiction 
variance to 𝜋 /3, the variance of the logistic distribution.  
Next, we computed unadjusted, weighted odds ratios for each jurisdiction and adolescent 
variable. Finally, we computed a weighted adjusted model that included all jurisdiction and 
adolescent predictors. We tested jurisdiction variables that prior studies have identified as 
potential correlates of provider recommendations for HPV vaccination: VFC program type,38 
Medicaid expansion,16 proportion of Hispanic residents,30 proportion of Black residents,30 
poverty rate,41 and proportion of rural residents.3 We also tested the following adolescent 
variables identified by prior research as correlates of provider recommendations: age,35 
gender,25,35 maternal education,26 household income-to-poverty ratio,25,35 race/ethnicity,6,25-27 
insurance type,27 whether the adolescent saw a VFC provider,87 and whether the adolescent had a 
recent doctors’ visit.27 We grand mean-centered key immunization jurisdiction variables (poverty 
rate, proportion of Hispanic residents, and proportion of Black residents) and group mean-
centered key adolescent variables (income-to-poverty ratio, race/ethnicity) in order to assess both 
adolescent and jurisdiction associations of these variables. We reported results as adjusted odds 
ratios (aOR). We conducted analyses using SAS version 9.4 with two-tailed statistical tests and 
critical alpha of 0.05. 
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Secondary to the primary analyses, we also conducted several sensitivity analyses to 
determine how robust our findings were to changes in measurement of our outcome variable and 
analysis. First, we reran analysis after adding in respondents who said they don’t know if they 
received a provider recommendation with those who reported that they did not receive a 
recommendation. We also examined whether our results differed between weighted and 
unweighted analysis.  For both sensitivity analyses, we found no differences in the statistical 
significance or direction of the adjusted ORs (data not shown).  
Results 
Sample 
The majority of adolescents (92%) resided in 46 jurisdictions that did not have a 
universal VFC program (Table 4.1). Less than half of adolescent residents (41%) resided in 33 
jurisdictions that had not expanded Medicaid coverage by 2018.  
Over half of adolescents had a mother with less than a college degree (57%). Over one-
third of adolescents (35%) had Medicaid, and relatively few (4%) were uninsured. A minority 
(15%) had not had a doctor’s visit in the past year, and roughly one in four (28%) had not seen a 
provider who participated in the VFC program. 
Correlates of Provider Recommendation  
Receipt of a provider recommendation ranged from 60% in Mississippi to 91% in 
Massachusetts. The ICC was .039 (T00 = 0.1344), indicating that about 4% of the variance 
associated with receipt of a provider recommendation was at the level of the immunization 
jurisdiction.  Adolescents living in jurisdictions that had not implemented Medicaid expansion 
had lower odds of receipt of a provider recommendation (74% vs. 80%, aOR:0.77; 95% CI: 
0.66:0.91; Table 4.2) compared to those in jurisdictions with Medicaid expansion. In addition, 
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adolescents had lower odds of receiving a provider recommendation if they lived in jurisdictions 
with higher poverty rate (aOR:0.64; 95% CI: 0.48:0.86). Immunization jurisdictions’ VFC 
program type and racial/ethnic compositions (i.e., proportion of Hispanic of Black residents) 
were not associated with receipt of a provider recommendation. 
Controlling for immunization jurisdiction characteristics, adolescents had lower odds of 
receiving a provider recommendation if they were male, had a mother with less than a college 
degree, or were uninsured (compared to privately insured). Adolescents had lower odds of 
receiving a provider recommendation if they came from households with a lower income-to-
poverty ratio, had not had a recent doctor’s visit, or did not see any provider participating in the 
VFC program. 
Discussion 
This study quantified the variation in receipt of provider recommendations for HPV 
vaccination between immunization jurisdictions and identified enabling characteristics of 
jurisdictions and adolescents associated with recommendations. We found that adolescents in 
jurisdictions with higher poverty rate or without Medicaid expansion less often received 
recommendations. When controlling for jurisdiction characteristics, adolescents who were male 
or of lower socioeconomic status (based on maternal education or income-to-poverty ratio) 
received recommendations less often. In addition to demographics, adolescents’ healthcare use 
was associated with recommendations; those who had not recently seen a provider or did not 
have a VFC-participating provider less often received recommendations. These findings suggest 
that the economic environment of an immunization jurisdiction may play a role in adolescents’ 




One goal of this study was to consider the relative importance of jurisdiction versus 
adolescent characteristics in associations with receipt of HPV vaccination recommendations. 
Although the relative contribution of jurisdiction factors such as living in a jurisdiction that does 
not have Medicaid expansion or has higher poverty rates is comparatively small (ICC=.04), the 
potential public health impact is substantial. Small ICCs can still indicate meaningful variation 
and are consistent with large scale factors, such as public policy, that affect a large swath of the 
population.89,90 It is possible that smaller geographic areas than used here, such as neighborhoods 
or zip codes, may have additional characteristics that influence whether an adolescent receives a 
recommendation. At the same time, the analyses point to the importance of an adolescent’s 
individual, family, and provider characteristics, such as gender, parental education, and provider 
participation in the VFC program, which were substantially associated with whether they receive 
a provider recommendation for HPV vaccination.  
Our study indicates that Medicaid expansion is a jurisdictional characteristic associated 
with receipt of a provider recommendation. Although the correlational nature of the study 
precludes our ability to make definitive causal assertions, our findings have several plausible 
explanations. Adolescents in Medicaid expansion jurisdictions may have better access to 
healthcare and greater healthcare use, which may translate to greater opportunity to receive a 
provider recommendation by having more visits or time with a provider. Indeed, studies show 
early evidence that Medicaid expansion states have demonstrated an increase in access to care 
and some preventive care measures among low-income adults.91 Alternatively, it is possible that 
jurisdictions with Medicaid expansion have more positive societal norms toward preventive 
healthcare, such as HPV vaccination. These norms could encourage parents to be more accepting 
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of HPV vaccination and providers to deliver recommendations more frequently and with less 
concern about raising a difficult and potentially time-consuming topic during visits.  
Contrary to our expectations, our multi-level analysis did not find recommendations to be 
more common for adolescents in jurisdictions with universal VFC programs, although seeing a 
VFC provider was associated with receiving a recommendation. The finding that adolescents 
who saw VFC providers were more likely to receive a recommendation is consistent with other 
studies in which VFC providers recommended HPV vaccination at a higher frequency87 and 
more often used best recommendation practices.92 VFC providers may potentially be more adept 
at recommending HPV vaccination because the VFC program reduces provider barriers, such as 
the upfront financial costs of obtaining and storing the HPV vaccine. Our measurement of VFC 
programs (universal vs. other) may have accounted for the null results. Possibly, other aspects of 
VFC programs not accounted for in these analyses (e.g., variation in the extent to which VFC 
programs deliver provider education or support) contribute to geographic disparities in receipt of 
a provider recommendation.  
Our study identified several important adolescent characteristics associated with receipt 
of a provider recommendation. Similar to other studies, lower maternal education, lower income-
to-poverty ratio, and lack of insurance were all associated with lower provider 
recommendations26,35 These characteristics remain important considerations, given the large 
proportion of variance in provider recommendations attributable to the individual level. 
In terms of implications for public health, our study demonstrates opportunities to better 
target intervention efforts by geography.  These findings suggest that some geographic areas may 
benefit from provider communication interventions more than others. While Rhode Island and 
Massachusetts have achieved higher saturation in provider recommendations, jurisdictions such 
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as Mississippi and Wyoming could benefit from evidence-based provider communication 
interventions.28 This study also highlighted some jurisdiction characteristics that may be 
important to consider when delivering provider communication interventions. Our study suggests 
that jurisdictions with higher poverty rates may need additional resources and support in terms of 
bolstering healthcare infrastructure, such as healthcare facilities and the number of providers.  
Strengths of this study include a large, nationally representative sample and use of 
multilevel modeling to examine both adolescent and jurisdiction-level model correlates. 
Limitations include a cross-sectional study design, which precludes causal inference. Although 
examining the impact of VFC program and Medicaid expansion on provider recommendations in 
an experimental design is impossible, future research could study associations between Medicaid 
expansion and provider recommendations over time to demonstrate whether change in Medicaid 
expansion consistently precedes change in provider recommendations. The low response rate for 
NIS-teen survey (RR: 26%) likely resulted in nonresponse bias.48 Likewise, our sample consisted 
of those adolescents with provider-verified vaccination records. Adolescents with provider-
verified vaccination records may differ in important ways (e.g., higher income, greater healthcare 
use) from adolescents without provider-verified records. Several jurisdiction variables (VFC, 
Medicaid expansion) could have benefited from more refined measurement. As noted above, 
aspects of the VFC program other than whether the program is universal (e.g., the extent to 
which they offer provider training and education) may be associated with receipt of a provider 
recommendation. The self-reported nature of our outcome variable, receipt of a provider 
recommendation, is another limitation of this study. Parents may have selectively over or 
underreported receipt of a provider recommendation (e.g., parents of younger children being 




Receipt of a provider recommendation demonstrates small but reliable variation as a 
function of immunization jurisdiction. Medicaid expansion and poverty rates are jurisdiction 
factors associated with receipt of a recommendation. Indicators of socio-economic disadvantage, 
such as lower maternal education, lower income-to-poverty ratio, and lack of insurance, are also 
associated with receipt of provider recommendation. Taken together, these findings suggest that 
efforts to increase HPV uptake should consider the multiple types of influence—
sociodemographic, provider, geographic, public policy—when attempting to increase HPV 




Table 4.1. Sample characteristics (n=17,251) 
 n (%)1 
Adolescent   
Age (m; SD) 15 (0.02) 
Gender   
Female 8,287 (49) 
Male 8,964 (51) 
Maternal education   
College degree or greater 8,217 (43) 
Some college or less 9,034 (57) 
Income-to-poverty ratio (m; SD) 0.75  (0.01) 
Insurance type   
Private 9,747 (53) 
Medicaid 5,350 (35) 
Uninsured 684   (4) 
Other2 1,470   (8) 
Race/ethnicity   
Non-Hispanic White  10.476 (53) 
Non-Hispanic Black 1,350 (14) 
Hispanic 3,595 (23) 
Non-Hispanic Other/Multiple Race 1,830 (10) 
Recent doctors’ visit (in past year)   
No 2,258 (15) 
Yes 14,993 (85) 
Provider participated in VFC   
No 4,142 (28) 
Yes 13,109 (72) 
Immunization Jurisdiction   
Universal VFC program type   
     Yes3  2,914   (8) 
     No 14,337 (92) 
Medicaid expansion   
Yes 10,045 (59) 
No 7,206 (41) 
Poverty rate (m; SD)4 14 (0.02) 
Proportion of Hispanic residents (m; SD) 14 (0.001) 
Proportion of Black residents (m; SD) 12 (0.001) 
Proportion of rural residents (m; SD)5 22 (0.11) 
1Percentages derived from NIS-teen data (all adolescent variables, universal VFC program type, Medicaid 
expansion) are weighted 
2Other insurance consists of Indian Health Service or military health care/Tri-care/Champus 
3Immunization jurisdictions with universal VFC program types are: Alaska, Idaho, Maine, Massachusetts, New 
Mexico, New Hampshire, Oregon, Vermont, Rhode Island, Washington 
4Proportion of total residents in jurisdiction with incomes below the Federal poverty level 







Table 4.2. Associations between adolescent and immunization jurisdiction characteristics and receipt of a 
provider recommendation 
  Number who 
received a 
recommendation/
Total adolescents (%)1 
Unadjusted model 
OR   (95% CI) 
  Adjusted model  
aOR   (95% CI) 
 Immunization jurisdiction       
 Universal VFC program       
      Yes (ref) 2,389/2,922 (82) 1.00 -- 1.00 -- 
      No 11,170/14,329 (78) 0.80 (0.62:1.04) 0.87 (0.69:1.09) 
 Medicaid expansion       
 Yes (ref) 8,110/10,045 (80) 1.00 -- 1.00 -- 
 No 5,449/7,206 (74) 0.71 (0.60:0.84)* 0.77 (0.66:0.91)* 
 Poverty rate -- -- 0.62 (0.46:0.84)** 0.64 (0.48:0.86)* 
 Proportion of Hispanic residents -- -- 1.00 (0.99:1.00) 1.00 (0.99:1.01) 
     53 
Proportion of Black residents -- --        0.99 (0.98:1.01) 1.01 (0.99:1.02) 
Proportion of rural residents -- -- 1.00 (0.99:1.00) 1.00 (0.99:1.00) 
Adolescents       
 Age  -- -- 1.05 (1.02:1.09)** 1.05 (1.02:1.09)* 
 Gender       
 Female (ref) 6,957/8,287 (82) 1.00 -- 1.00 -- 
 Male 6,602/8,964 (72) 0.53 (0.48:0.57)** 0.52 (0.46:0.59)** 
 Maternal education       
 College degree or greater (ref) 6,970/8,217 (83) 1.00 -- 1.00 -- 
 Some college or less 6,589/9,034 (73) 0.51 (0.48:0.55)** 0.70 (0.61:0.80)** 
 Income-to-poverty ratio -- -- 0.72 (0.67:0.77)** 0.84 (0.77:0.90)** 
 Insurance status       
 Private (ref) 6,587/9,747 (83) 1.00 -- 1.00 -- 
 Medicaid 3,922/5,350 (72) 0.68 (0.62:0.75)* 0.88 (0.75:1.04) 
 Other 975/1,470 (74) 0.82 (0.70:0.96)* 0.74 (0.63:0.88)** 
 Uninsured 422/684 (60) 0.35 (0.29:0.42)** 0.57 (0.45:0.72)** 
 Race/ethnicity       






AIC2  17,719.40 -- 17,124.70 -- 
BIC3  17,723.40 -- 17,163.20 -- 
ICC4  0.04 -- -- -- 
1percentages are weighted; 2Akaike Information Criteria; 3Bayesian Information Criteria; 4Intraclass Correlation 
*p<0.05  **p<0.01 
 
 
    Non-Hispanic Black 1,035/1,350 (74) 0.88 (0.73:1.08) 0.98 (0.80:1.20) 
    Hispanic 2,544/3,595 (73) 0.66 (0.56:0.77)** 0.90 (0.76:1.05) 
 Non-Hispanic Other/Multiple 
race 
1,447/1,830 (79) 1.03 (0.89:1.19) 1.04 (0.89:1.21) 
 Recent doctors’ visit (in past year)       
 Yes (ref) 12,061/14,993 (80) 1.00 -- 1.00 -- 
 No  1,498/2,258 (66) 0.50 (0.43:0.57)** 0.56 (0.48:0.65)** 
 Provider participated in VFC       
 Yes (ref) 10,333/13,109 (78) 1.00 -- 1.00 -- 




CHAPTER FIVE. EXAMINING GEOGRAPHIC DISPARITIES IN HPV 
VACCINATION (AIM 2) 
Introduction 
Human papillomavirus (HPV) vaccination could eliminate most HPV-associated 
cancers,2 but low uptake currently limits the potential of this cancer prevention tool in the United 
States (US).3 The US Advisory Committee on Immunization Practices (ACIP) recommends that 
adolescents receive two doses of HPV vaccine prior to age 13.4 However, only 54% of 
adolescents, age 13-17, were up-to-date by 2019.1 Likewise, over one-fifth (22%) did not receive 
a provider recommendation for HPV vaccination,3 one of the strongest and most consistent 
predictors of HPV vaccine uptake.5-9 To date, research has primarily focused on individual 
interventions and less attention has been given to policy or organizational factors that might 
impact HPV vaccination.93,94 
Substantial geographic disparities in HPV vaccination suggest that geographic 
characteristics may influence an adolescent’s likelihood of vaccination. HPV vaccination 
coverage ranges from 31% in Mississippi to 79% in Rhode Island. Research has identified policy 
level factors, such as the Vaccines for Children (VFC) program type and Medicaid expansion, as 
correlates of state disparities in HPV vaccination coverage.16 The VFC program is a federally 
funded program that offers vaccines at no cost to adolescents who may not otherwise be able to 
pay.15 States that offer vaccines to all adolescents (universal coverage) demonstrate a 10-13% 
increase in HPV vaccination coverage compared to states without universal coverage.38 
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Likewise, adolescents living in states with Medicaid expansion have a higher likelihood of HPV 
vaccination than adolescents in states without Medicaid expansion.16  
Geographic variation in receipt of a provider recommendation may further explain 
geographic variation in HPV vaccination. Receipt of a provider recommendation ranges from 
60% in Mississippi to 91% in Massachusetts.3 In ecological analyses focusing on male 
adolescents, states’ proportions of adolescents who report receiving a provider recommendation 
also correlate with HPV vaccination coverage.14  
No studies I am aware of have examined how geographic variation in provider 
recommendations correlates with likelihood of HPV vaccination in a multilevel context. A 
multilevel analysis can determine the relative contribution of area-level variation in provider 
recommendations to HPV vaccination, above and beyond an individual’s receipt of a provider 
recommendation. Areas with higher proportions of provider recommendations could suggest 
important characteristics of the environment, such as positive provider norms around HPV 
vaccination, that could lead providers to recommend the vaccine more consistently. Identifying 
the extent to which provider recommendations at the area-level influence an adolescent’s 
likelihood of HPV vaccination could highlight an important contextual characteristic to explain 
geographic disparities in HPV vaccination coverage.  
Thus, this study aims to better understand the geographic and adolescent association of 
provider recommendations on HPV vaccination. Our geographic unit of analysis is the 
immunization jurisdiction, or state and local areas that receive federal grants to finance 
immunization programs such as the Vaccines for Children (VFC) program. We also examine 
jurisdiction characteristics (e.g., VFC program type, Medicaid expansion, poverty rates) and 
adolescent characteristics that have been associated with HPV vaccination and/or receipt of a 
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provider recommendation. This study is designed to enhance our understanding of the role of 
provider recommendations in geographic disparities in HPV vaccination coverage and identify 
potentially modifiable correlates of HPV vaccination at the jurisdiction level. 
Methods 
Data Sources and Sample 
This study used data from the 2018 National Immunization Survey (NIS)-Teen joined 
with data from the Association for Immunization Managers (AIM) survey and other publicly 
available datasets. NIS-Teen is a national, annual survey conducted by the Centers for Disease 
Control and Prevention (CDC) to estimate national vaccination coverage among adolescents ages 
13-17 years.48 NIS-Teen data collection occurs in two phases: 1) a computer-assisted telephone 
household interview with a parent or guardian of an adolescent ages 13-17 that collects data on 
the adolescent’s sociodemographics and health insurance status; and, 2) a mailed questionnaire 
to the adolescent’s providers to assess vaccination status based on the adolescent’s medical 
record and to determine whether the provider orders vaccines from the Vaccines for Children 
(VFC) program. NIS-Teen uses separate sampling weights for each phase (telephone interview 
and provider questionnaire) of data collection.48 Sampling weights represent the approximate 
number of adolescents that one adolescent in the sample represents, adjusted for non-response as 
well as age, gender, race, and ethnicity classes based on population estimates produced by the 
US Census Bureau. NIS-teen uses provider-verified reports of vaccination to derive national 
vaccination coverage estimates.  
In 2018, NIS-teen used a single-frame cellphone random digit dialing (RDD) sampling 
strategy. A sample of 15.5 million telephone numbers yielded 38,706 household interviews 
(American Association for Public Opinion Research Response Rate 3: 26%).48,70 Of the those 
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household interviews, NIS-Teen subsequently obtained provider-verified reports for 18,700 
adolescents (49%).48 We excluded those without complete data on the provider recommendation 
variable (n=1,449) to obtain our final sample consisted of 17,251 adolescents. 
The Association for Immunization Managers (AIM), a nonprofit organization that 
supports Section 317 Immunization Grantees, administers an annual survey to program managers 
of immunization programs to collect data on the activities, staffing and needs of each program. 
The 2017 AIM survey collected data from grantees on each immunization program’s 
participation in the VFC program.51 This study used data from the 56 Section 317 Immunization 
Grantee jurisdictions in the domestic US. These immunization jurisdictions consist of 6 regional 
areas (Washington, DC; Houston, TX; San Antonio, TX; Philadelphia, PA; New York City, NY; 
and, Chicago, IL), 4 “rest of state” areas (Texas, Pennsylvania, New York, and Illinois), and 46 
full states. 
We used several publicly available data sources to gather information on immunization 
jurisdictions. The 2010 US Census reported data on the racial and ethnic composition of each 
immunization jurisdiction and poverty rates. The Kaiser Family Foundation provided 
information on which states have implemented Medicaid expansion as of 2018.53 The National 
Center for Health Statistics provided information on the proportion of individuals living in rural 
areas (defined as non-metropolitan statistical areas [MSA]).54 
Measures 
We identified measures from a conceptual framework identified in Chapter Four, based 
on Andersen’s Model of Healthcare Utilization.37 
HPV vaccination initiation. NIS-Teen collects information from adolescent’s providers 
on the number of HPV vaccination shots the adolescent has received.  Adolescents who received 
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at least 1 dose of the HPV vaccine were coded as yes (1) and those who had not received any 
doses were coded as no (0). 
Proportion of provider recommendations.  We calculated the proportion of adolescents in 
each immunization jurisdiction that received a provider recommendation using NIS-Teen’s 
household survey. NIS-Teen’s household survey asked parents whether “a doctor or other health 
care professional ever recommended that [TEEN’S NAME] receive HPV shots”. We coded 
responses as: 0 (“no,”) versus 1 (“yes”). We then summed the number of adolescents in each 
jurisdiction who had received a provider recommendation and divided that sum by the total 
number of adolescents in the jurisdiction. 
VFC program type. Immunization jurisdictions’ VFC programs have different criteria for 
determining which adolescents are served and which vaccines are distributed through the VFC 
program. Nationally, adolescents are eligible for VFC vaccines if they meet one of the following 
criteria: 1) uninsured or underinsured; 2) American Indian or Alaskan Native; 3) Medicaid-
eligible. In addition, some immunization jurisdictions have expanded the VFC program to cover 
additional adolescents. The most expansive VFC program type is “universal,” in which all 
adolescents are eligible to receive all ACIP-recommended vaccines through the VFC program, 
regardless of their insurance status or ability to pay. Other VFC program types include 
distributing: 1) select vaccines to adolescents meeting VFC criteria (VFC-select); 2) all vaccines 
to adolescents meeting VFC criteria (VFC-only); and, 3) select vaccines to all adolescents 
(universal-select).15 We assessed immunization jurisdictions’ VFC program type as whether their 
eligibility is universal (0) or other (VFC-select, VFC-only, and universal-select) (1). 
Medicaid Expansion. Under the United States’ (US) Affordable Care Act, some states 
expanded Medicaid programs to cover all people under age 65 with household incomes up to 138 
 
60 
percent of the federal poverty level. We coded each jurisdiction as having implemented Medicaid 
expansion (0) or not having implemented Medicaid Expansion (1), as of January 2018. 
Poverty rate. Jurisdictions’ poverty rate consisted of the number of residents with 
incomes below the Federal poverty level divided by the total number of residents in each 
jurisdiction, as estimated by the 2010 U.S. Census. We then divided poverty by 10, so that one 
unit of change in a multilevel model would correspond to a 10% change in poverty rates. 
Proportion of Hispanic residents. We assessed the proportion of Hispanic residents as the 
number of Hispanic residents in an immunization jurisdiction divided by the total number of 
residents in that immunization jurisdiction, as estimated by the 2010 U.S. Census. 
Proportion of Black residents. We assessed the proportion of Black residents as the 
number of Black residents in an immunization jurisdiction divided by the total number of 
residents in that immunization jurisdiction, as estimated by the 2010 U.S. Census. 
Proportion of rural residents. We assessed the proportion of rural residents as the number 
of residents who lived in non-metropolitan statistical areas (MSAs), as estimated by the National 
Center for Health Statistics, divided by the total number of residents in that immunization 
jurisdiction, as estimated by the 2010 U.S. Census. MSAs are defined as areas with at least 
50,000 residents that have an urban nucleus of at least 1,000 persons per square mile together 
with adjoining territory of at least 500 persons per square mile.54 
Adolescent characteristics. NIS-teen provided additional independent variables about the 
adolescents included in our analysis: age in years, gender (male or female), and race/ethnicity 
(Hispanic, Non-Hispanic Black, Non-Hispanic White, Non-Hispanic Other). 
NIS-teen also provided additional independent variables about the adolescent’s 
household included in our analysis: maternal education (some college or less vs. college degree 
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or more), income-to-poverty ratio (adolescent’s household income divided by the applicable 
Federal poverty income), and health insurance type (private, Medicaid, other insurance, 
uninsured). 
NIS-teen provided additional independent variables about the adolescent’s provider 
included in our analysis: whether any of the adolescent’s providers ordered vaccines from the 
VFC program (yes/no), whether the adolescent had a recent doctor’s visit (yes/no), and whether 
the adolescent had received a provider recommendation (yes/no).  
NIS-teen imputed missing values using sequential hot-deck method in which missing 
values are replaced with observed values from similar respondents.48 
Data Analysis 
We first computed weighted descriptive statistics (e.g., mean, percentages) on all 
variables. To identify correlates of HPV vaccination initiation, we used a weighted multilevel 
logistic regression model that nested adolescents (level 1) within immunization jurisdictions 
(level 2). According to best practice recommendations, we rescaled provider-confirmed sampling 
weights that account for selection and non-response probability to fit the multilevel nature of the 
data.88 Using PROC GLIMMIX with maximum likelihood estimation with adaptive quadrature, 
we obtained the intraclass correlation (ICC) of HPV vaccination initiation clustered by 
immunization jurisdiction. The ICC represents the proportion of total variance in HPV 
vaccination initiation that is explained by differences between immunization jurisdictions. 
Because our binary outcome does not include within-jurisdiction residuals, we automatically set 
the within-jurisdiction variance to 𝜋 /3, the variance of the logistic distribution.56 
Next, we assessed the odds ratio of each jurisdiction and adolescent variable 
independently in bivariate analyses. Finally, we added all jurisdiction variables into a fixed-
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effects multilevel logistic regression model. Jurisdiction variables that prior research identified as 
potential correlates of HPV vaccination initiation: provider recommendations,14 VFC program 
type,38 Medicaid expansion,16 proportion of Hispanic residents,30 proportion of Black residents,30 
poverty rate,41 and proportion of rural residents.3 We also added the following adolescent 
variables identified by prior research as correlates of HPV vaccination initiation: provider 
recommendation,5 age,35 gender,25,35 maternal education,26 household income-to-poverty 
ratio,25,35 race/ethnicity,6,25-27 insurance type,27 whether the adolescent saw a VFC provider,87 and 
whether the adolescent had a recent doctors’ visit.27 We grand mean-centered key immunization 
jurisdiction variables (state proportion of provider recommendations, poverty rate, proportion of 
Hispanic residents, and proportion of Black residents) and group mean-centered key adolescent 
variables (provider recommendation, income-to-poverty ratio, race/ethnicity) in order to assess 
both adolescent and jurisdiction associations of these variables. We reported results as adjusted 
odds ratios (aOR). We conducted analyses in SAS version 9.4 using two-tailed statistical tests 
and a critical alpha of 0.05. 
We also conducted several exploratory analyses.  We examined two cross-level 
interactions with an adolescent’s receipt of a provider recommendation to determine whether the 
association between provider recommendations and HPV vaccination initiation differed based on 
jurisdiction characteristics. This analysis could demonstrate that receipt of a provider 
recommendation in one jurisdiction is more strongly associated with HPV vaccination initiation 
than in another jurisdiction. We examined whether the association between receipt of a provider 
recommendation and HPV vaccination initiation differed depending on whether the adolescent 
lived in a jurisdiction with higher or lower proportions of provider recommendations. Because 
the interaction between jurisdiction’s proportion of provider recommendations and receipt of a 
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provider recommendation was not statistically significant, we do not report on it further. Second, 
we examined whether the strength of the association between receipt of a provider 
recommendation and HPV vaccination initiation differed based on whether the adolescent lived 
in a Medicaid expansion jurisdiction. Appendix B includes a description of the analytic 
procedures and results of this cross-level interaction. Finally, we used a multilevel mediation 
model to examine whether receipt of a provider recommendation mediated associations between 
jurisdiction and adolescent variables and HPV vaccination. Appendix C includes a description of 
the analytic procedures and results of the multilevel mediation analysis. 
Results 
Sample 
Most adolescent residents (92%) resided in 46 jurisdictions without universal VFC 
programs (Table 5.1). Less than half of adolescent residents (41%) resided in 33 jurisdictions 
that had not expanded Medicaid coverage by 2018.  
Over half of adolescents had a mother with less than a college degree (57%). Over one-
third of adolescents (35%) had Medicaid, and few (4%) were uninsured. A minority (15%) had 
not had a recent doctor’s visit in the past year, and over one-quarter (28%) had not seen a 
provider who participated in the VFC program. 
Correlates of HPV Vaccination Initiation 
The intraclass correlation (ICC) indicated that about 4% of the total variance in HPV 
vaccination occurred at the level of the immunization jurisdiction (T00 :0.15; ICC=0.04). 
Adolescents had higher odds of HPV vaccination initiation if they lived in jurisdictions with 
higher proportions of provider recommendations (aOR:1.53; 95% CI:1.28:1.82; Table 5.2) or 
higher poverty rates (aOR:1.40; 95% CI:1.003:1.95). Adolescents had lower odds of HPV 
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vaccination initiation if they lived in jurisdictions without universal VFC programs compared to 
jurisdictions with universal VFC programs (68% vs. 77%, aOR:0.79; 95% CI:0.64:0.98). 
Although living in a jurisdiction without Medicaid expansion was associated with lower odds of 
HPV vaccination initiation in bivariate analysis, it was not in the adjusted model.  HPV 
vaccination initiation was not significantly associated with living in a jurisdiction with higher 
proportions of Black, Hispanic, or rural residents. 
Controlling for jurisdiction characteristics, adolescents had higher odds of initiating HPV 
vaccination if they were older, or Hispanic or non-Hispanic Black (versus non-Hispanic White). 
Adolescents had lower odds of initiating HPV vaccination if they were male, had a mother with 
less than a college degree, had a lower income-to-poverty ratio, were uninsured, had not had a 
recent doctors’ visit or had not seen a provider participating in the VFC program.  
Discussion 
Our study found small, but potentially meaningful, variation in HPV vaccination among 
jurisdictions, although most variation occurred within jurisdictions. Controlling for adolescent 
characteristics, living in a jurisdiction with a higher proportion of provider recommendations was 
associated with higher likelihood of HPV vaccination, whereas living in a jurisdiction without a 
universal VFC program was associated with lower likelihood of HPV vaccination. Our 
multilevel analysis also identified adolescent sociodemographic and health utilization 
characteristics associated with HPV vaccination, after controlling for jurisdiction characteristics. 
Our study is novel in demonstrating that living in a jurisdiction with higher proportions of 
provider recommendations was associated with HPV vaccination, above and beyond an 
individual adolescent’s receipt of a recommendation. Jurisdictions with higher proportions of 
recommendations could share important characteristics of the environment, such as positive 
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provider norms around HPV vaccination, that could lead providers to recommend the vaccine 
more consistently. Alternately, a jurisdiction’s proportion of provider recommendations could act 
as a proxy variable for other characteristics, such as healthcare infrastructure, that facilitate HPV 
vaccination. For example, jurisdictions with higher proportions of provider recommendations 
may have more providers or healthcare facilities, allowing for more opportunities for adolescents 
to initiate HPV vaccination. Future research should explore potential variables (e.g., provider 
norms, healthcare infrastructure) that could explain why jurisdictions with higher proportions of 
provider recommendations might have higher HPV vaccination coverage.  
Consistent with prior research, our study found that the robustness of the VFC program 
was also an important jurisdiction characteristic that correlated with HPV vaccination initiation. 
Of note, VFC was associated with HPV vaccination at both the jurisdiction and adolescent level.  
Adolescents living in jurisdictions without universal VFC programs and who do not see a VFC 
provider less often received HPV vaccination. By making vaccines available to all adolescents, 
jurisdictions with universal VFC programs reduce barriers such as access and cost. Likewise, 
VFC programs with universal coverage may be more effective at reaching providers for 
education and training. VFC providers receive training through CDC’s Immunization Quality 
Improvement for Providers (IQIP) program that focuses on improving vaccination practices 
through various strategies, including provider communication training. 
Our study identified numerous adolescent characteristics also correlated with HPV 
vaccination. Our study aligned with prior research assessing individual-level differences in HPV 
vaccination in finding that adolescents with lower income,3,24,27,31 with Medicaid (compared to 
private insurance),86 and racial/ethnic minorities3,24,39 were more likely to initiate HPV 
vaccination. This finding could suggest system-level differences in the ways these adolescents 
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receive care. These adolescents may receive care from safety-net clinics and health departments, 
which may be more likely to participate in the VFC program and/or to recommend HPV 
vaccination. This idea is further supported by the finding that uninsured adolescents were less 
likely to receive the first dose of HPV vaccination, similar to other research.5,25,27,30  
In terms of implications for public health, our study suggests that certain jurisdictions 
may share important characteristics, such as norms, that facilitates HPV vaccination. Given the 
association between jurisdictions’ proportion of provider recommendations and HPV 
vaccination, future research should explore what specifically about these areas makes providers 
more likely to recommend HPV vaccination. Our study also highlights that certain jurisdictions 
may be in greater need of interventions than others. Our findings also suggest jurisdictions with 
lower HPV vaccination coverage may have a very different capacity for delivering these 
interventions in an effective manner. Future studies should address how best to tailor 
interventions based on a jurisdiction’s norms and infrastructure. 
Strengths of this study include a nationally representative sample, a provider-verified 
outcome of HPV vaccination, and a novel focus on how provider recommendations could have a 
contextual relationship with HPV vaccination. Limitations include a cross-sectional design, 
which precludes causal inference, and a low response rate which could result in non-response 
bias.  Likewise, limiting the sample to provider-verified records may reduce generalizability, as 
adolescents with provider-verified records may differ on certain key characteristics than those 
without provider-verified records. Several jurisdiction variables, notably the VFC program and 
Medicaid expansion, could have benefited from more refined measurement. For example, 
jurisdictions’ VFC programs may differ in the number of providers they reach or the amount of 
training they offer to providers; these differences could lead to differences in HPV vaccination 
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coverage. Additional jurisdiction characteristics could also account for geographic variation in 
HPV vaccination; parent norms and beliefs could account for variation in HPV vaccination 
coverage. Likewise, differences in healthcare infrastructure (e.g., the number of providers 
available to adolescents) could account for geographic variability. Finally, receipt of a provider 
recommendation is a self-reported variable that could be subject to recall bias. 
Conclusions 
This study highlights the importance of considering context when studying provider 
recommendations and HPV vaccination. Jurisdictions’ proportion of provider recommendations, 
and the VFC program are important geographic characteristics to consider in HPV vaccination 
research. Variables of socioeconomic disadvantage are associated with higher odds of HPV 





Table 5.1. Sample characteristics (n=17,251) 
 n %1 
Adolescent   
Age (m; SD) 15 (0.02) 
Gender   
Female 8,287 (49) 
Male 8,964 (51) 
Maternal education   
College degree or greater 8,217 (43) 
Some college or less 9,034 (57) 
Income-to-poverty ratio (m; SD) 0.75  (0.01) 
Insurance type   
Private 9,747 (53) 
Medicaid 5,350 (35) 
Uninsured 684   (4) 
Other2 1,470   (8) 
Race/ethnicity   
Non-Hispanic White  10,476 (53) 
Non-Hispanic Black 1,350 (14) 
Hispanic 3,595 (23) 
Non-Hispanic Other/Multiple Race 1,830 (10) 
Recent doctors’ visit (in past year)   
No 2,258 (15) 
Yes 14,993 (85) 
Provider participated in VFC   
No 4,142 (28) 
Yes 13,109 (72) 
Immunization Jurisdiction   
Proportion of provider recommendations (m; SD) 75 (0.84) 
Universal VFC program    
     Yes3  2,914   (8) 
     No 14,337 (92) 
Medicaid expansion   
Yes 10,045 (59) 
No 7,206 (41) 
Poverty rate (m; SD)4 14 (0.02) 
Proportion of Hispanic residents (m; SD) 14 (0.001) 
Proportion of Black residents (m; SD) 12 (0.001) 
Proportion of rural residents (m; SD)5 22 (0.11) 
1Percentages derived from NIS-teen data (all adolescent variables, universal VFC program type, Medicaid 
expansion) are weighted 
2Other insurance consists of Indian Health Service or military health care/Tri-care/Champus 
3Immunization jurisdictions with universal VFC program types are: Alaska, Idaho, Maine, Massachusetts, New 
Mexico, New Hampshire, Oregon, Vermont, Rhode Island, Washington 
4Proportion of total residents in jurisdiction with incomes below the Federal poverty level 









Total adolescents (%)1 OR (95% CI) aOR (95% CI) 
     
Immunization Jurisdiction     
Proportion of Provider 
Recommendations 
-- -- 1.56 (1.35:1.80)** 1.53 (1.28:1.82)** 
Universal VFC program    
Yes (ref) 2,180/2,922 (77) 1.00 --   1.00 -- 
No 6,674/14,329 (68) 0.72 (0.54:0.84)** 0.79 (0.64:0.98)* 
Medicaid expansion      
Yes (ref)  7,255/10,045 (71) 1.00    1.00 -- 
No 4,651/7,206 (64) 0.67 (0.55:0.82)** 0.86 (0.73:1.02) 
                  69 
Poverty rate -- -- 0.91  (0.66:1.26) 1.40 (1.003:1.95)* 
Proportion of Hispanic residents -- -- 1.00 (0.99:1.01) 1.00 (0.99:1.01) 
Proportion of Black residents  -- -- 1.01  (1.00:1.02) 1.00 (0.99:1.01) 
Proportion of rural residents 0.99 (0.98:1.00) 0.99 (0.99:1.01) 
Adolescents     
Receipt of provider 
recommendation 
    
No (ref) 1,681/3,692 (46) 1.00 -- 1.00 -- 
Yes 10,225/13,559 (75) 3.54 (3.28:3.83)** 3.61 (3.33:3.91)** 
Age --  -- 1.07 (1.05:1.10)* 1.09 (1.06:1.11)* 
Gender      
Female (ref) 5,928/8,287 (70) 1.00 -- 1.00 -- 
Male 5,978/8,964 (67) 0.80 (0.75:0.85)* 0.90 (0.84:0.96)* 
Maternal education      
College degree or greater (ref) 5,745/9,034 (68) 1.00 -- 1.00 -- 
Some college or less 6,161/9,034 (69) 0.99 (0.93:1.01) 0.87 (0.80:0.95)* 
Income-to-poverty ratio -- - 1.17 (1.13:1.21)** 1.10 (1.05:1.16)* 
Insurance status      








Total adolescents (%)1 OR (95% CI) aOR (95% CI) 
Medicaid 3,922/5,350 (74) 1.43 (1.34:1.54)* 1.29 (1.16:1.43)* 
Uninsured 422/684 (57) 0.76 (0.66:0.89)** 0.80 (0.67:0.95)* 
Other 975/1,470 (65) 1.09 (0.98:1.21)** 1.31 (1.16:1.48)* 
Race/ethnicity       
Non-Hispanic White 6,877/10,476 (64) 1.00 -- 1.00 -- 
Hispanic 2,722/3,595 (75) 1.74 (1.59:1.90)** 1.99 (1.77:2.22)* 
Non-Hispanic Black 999/1,350 (73) 1.27 (1.12:1.44)** 1.53 (1.36:1.73)* 
Non-Hispanic Other/Multiple 
Race 
1,308/1,830 (66) 1.09 (0.98:1.21) 1.25 (1.11:1.42)* 
Recent doctors’ visit (in past 
year) 
      
 
Yes (ref) 10,592/14,993 (70) 1.00 -- 1.00 -- 
No 1,314/2,258 (61) 0.58 (0.53:0.63)** 0.65 (0.59:0.71)*      70 
Provider participated in VFC       
Yes (ref) 9,290/13,109 (71) 1.00  -- 1.00 -- 
No 2,616/4,142 (62) 0.69 (0.65:0.75)** 0.77 (0.71:0.84)* 
AIC   22,904.96 -- 19,337.59 -- 
BIC   22,909.01 -- 19,382.15 -- 
ICC   0.04 -- -- -- 
1percentages are weighted; *p<0.05    **p<0.01 
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CHAPTER SIX. PROVIDER RESPONSE AND FOLLOW-UP TO PARENTAL 
DECLINATION (Aim 3) 
Introduction 
HPV vaccination could prevent the majority of HPV cancers,2 but vaccine uptake 
remains suboptimal.1  One factor contributing to low uptake is parental refusal and intentional 
delay (or “declination”) of HPV vaccination. HPV vaccination declination ranges from 30% to 
36% in national surveys of US parents.13,42  These proportions are far higher than for other 
adolescent vaccines, such as tetanus, diphtheria, and acellular pertussis (~2%) or meningococcal 
vaccine (5%).43  Although research consistently demonstrates the importance of provider 
communication in initially recommending HPV vaccination, 7,28,95,96 little is known about how 
providers can effectively communicate with parents who decline HPV vaccination to later 
vaccinate (or “secondary acceptance”). 
Providers can encourage parents who decline through actions such as responding to 
declination during the visit or following-up after the visit. Existing research suggests that 
additional action from a provider may be effective at increasing HPV vaccination at a later 
timepoint.12 For example, one study found that parents had higher odds of later HPV vaccination 
if they initially received a high-quality HPV vaccination recommendation and if they received 
follow-up counseling from a provider. However, only about half of parents who declined HPV 
vaccination (52%) reported receiving follow-up counseling.12  Providers frequently report 
offering these parents reassurances of safety, providing written information and asking questions
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 to probe concerns.45 How these specific actions are associated with parents’ HPV vaccination 
perceptions and behavior is unknown. 
The Increasing Vaccination Model offers a useful framework to understand how provider 
communication might increase secondary acceptance.47 This model proposes that three general  
psychological principles motivate vaccination: 1) thoughts and feelings, such as risk appraisals 
and vaccine confidence; 2) social processes, such as social norms, altruism; and 3) direct 
behavior change, such as reminders and prompts, that leverage favorable intentions to vaccinate. 
The model highlights direct behavior change as the most effective and plentiful mechanism on 
which to intervene. Provider response and follow-up to parental declination may address these 
psychological processes, with providers uniquely positioned to effectively intervene on direct 
behavior change when parents decline HPV vaccination. A provider addressing thoughts and 
feelings by actively responding to parents’ questions and concerns during the visit could be a 
necessary step when parents decline HPV vaccination, although possibly less efficacious than 
direct behavior change. Providers can follow-up after the visit with reminders to cue the parent to 
action. Thus, a provider can increase secondary acceptance through an active response during the 
visit or follow-up after the visit. 
This study sought to characterize how providers respond during the visit and follow-up 
after the visit to parental declination of HPV vaccination and to determine how a provider’s 
actions are associated with secondary acceptance. We also compared how parents reported that a 
provider should respond or follow-up and how providers did respond or follow-up. 
Understanding how physicians can effectively communicate with parents who decline 





Data Source and Sample 
We conducted an online, cross-sectional survey of US parents of adolescents from 
November 2017 to January 2018. Study participants were members of an existing, national panel 
of non-institutionalized adults maintained by a survey company. The company constructed the 
panel from a probability-based sample of US households using address-based sampling frames. 
Eligible respondents were parents of at least one 9- to 17-year-old child who either had not 
initiated the HPV vaccine series or had received only the first dose. We focused on parents of 
children who were not fully vaccinated because they are a high priority for vaccine promotion 
efforts. Parents with more than one eligible child answered survey items about the child with the 
most recent birthday.  
The survey company contacted a random sample of 2,857 parents from the panel via 
email to invite survey participation. A total of 1,834 parents responded by visiting the survey 
website and accessing the screener to confirm having an age-eligible child with 0-1 dose of HPV 
vaccine.  Of these parents, 1,313 (72%) met eligibility criteria, provided informed consent, and 
completed some portion of the survey.  After we excluded 50 panelists who did not complete at 
least two-thirds of the survey, the overall sample for the survey consisted of 1,263 parents. The 
response rate was 61%, using American Association for Public Research Response Rate 4 
calculation.70 The analytic sample for this study consisted of 447 parents who reported refusing 
or delaying HPV vaccination during an initial discussion with their child’s provider about HPV 
vaccine. The Institutional Review Board at the University of North Carolina at Chapel Hill 




Secondary acceptance. Among parents who declined HPV vaccination during the initial 
discussion with their provider, we coded those who reported at the time of the survey that their 
child had received at least 1 dose as having achieved HPV vaccination. We measured the number 
of doses of HPV using the question, “How many shots of the HPV vaccine has [NAME] had?” 
Provider active response during the visit.  The survey measured whether a provider 
actively responded to parents who declined HPV vaccination by asking about actions that 
providers took after the parent initially declined. We coded parents who received an active 
response from their provider if parents reported that their provider did one or more of the 
following: “give more information”, “offer to talk about the HPV vaccine again at a later visit”, 
“try to change your mind”, or “ask you to sign a form confirming that you refuse to vaccinate.” 
Those who did not receive an active response from their provider are those whose provider only 
did one or more of the following: “accept your decision”, “move on with the visit without much 
comment”, or “none of the above”. 
Provider follow-up after the visit.  The survey measured whether a provider followed-up 
after the visit by: “scheduling another visit to talk about it again”, “bringing it up again at the 
next check-up”, or “sending a reminder (phone, text, email or mail)”. We coded those who 
received any follow-up versus those who received none of these.   
Parents’ negative decisional affect. The survey measured parents’ affect during the visit 
using a single item, “At that visit, how did you feel about your HPV vaccine decision?” Parents 
reported that they felt one or more of the following: worried, unsure, annoyed, uncomfortable, at 
ease, confident, relieved, optimistic, or none of these. We dichotomized parents who reported 
feeling any negative emotion (e.g., annoyed, worried, uncomfortable or unsure) versus only 
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positive emotions (at ease, confident, relieved, optimistic) or “none of these.” Correlations 
between negative affect items are shown in Appendix D, Table D.1. 
Parents’ discomfort with the visit. The survey measured parents’ discomfort with the visit 
using one item, “How did your conversation about the HPV vaccine affect that visit with 
[NAME]’s doctor or health care provider?” The response option consisted of a five-level ordinal 
scale from “much less comfortable” (5) to “much more comfortable” (1).  
Parents’ preferred provider response. The survey measured whether a provider should do 
one or more of the following to respond when a parent decides not to get HPV vaccine: “accept 
your decision”, “give you more information”, “offer to talk about the HPV vaccine again at a 
later visit”, “try to change your mind”, “ask you to sign a form confirming that you refuse to 
vaccinate”, “move on with the visit without much comment”, or “none of these”. 
Parents’ preferred provider follow-up. The survey measured whether a provider should 
do one or more of the following to follow-up when a parent decides not to get HPV vaccine: 
“schedule another visit to talk about it again”, “bring it up again at the next check-up”, “send a 
reminder (phone, text, email or mail)”, or, “none of these”. 
Provider recommendation. The survey measured whether the adolescent had received a 
recommendation for HPV vaccination from a provider (yes [1] or no [0]). 
Adolescent and family characteristics.  The survey measured child’s age, child’s sex at 
birth (male vs. female), and race/ethnicity (non-Hispanic Black, non-Hispanic white, Hispanic, 
and multiple races/other race). The survey company provided annual household income, and 




For each provider response and follow-up action, we used chi-square tests to assess 
whether a greater proportion of parents reported that their provider should take an action than did 
take the action.  
We specified a multivariable logistic regression model examining secondary acceptance 
as the dependent variable and provider active response during the visit and provider follow-up 
after the visit as the independent variables. The model included demographic covariates that 
correlate with HPV vaccination in previous studies: provider recommendation for HPV 
vaccination, child’s sex at birth, child’s age, parent’s education, race/ethnicity, and annual 
household income.3,8,42,72,73 Conducted in SAS version 9.4, unweighted statistical tests were two-
tailed with a critical α of 0.05. 
We conducted sensitivity analyses to determine how sensitive our model was to changes 
in analysis and coding.  First, we removed parents who refused HPV vaccination and re-ran the 
model with parents who delayed HPV vaccination only. Parents who delayed may differ from 
those who refused in being less opposed to vaccination and may be more receptive to provider 
response and follow-up. Due to the small sample size (n=3), we were unable to examine a model 
including only parents who initially refused but later vaccinated their child. Second, we 
examined a model with a recoded version of the negative decisional affect variable that excluded 
“unsure”, as that emotion could be less negative than others (e.g., annoyed, confused, worried). 
Third, we reran the model after removing parents who reported “none of these” when reporting 
negative decisional affect items as it’s unclear whether parents who selected this response felt 
another negative affect or another positive affect. Fourth, we reran the model after removing 
parents who reported that a provider responded “none of these” when asked how a provider 
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responded as it’s unclear whether these parents did not receive any active response or received a 
response that was not listed in the survey. Finally, we examined whether the model differed if we 
removed the item “tried to change the parent’s mind” from the provider active response variable. 
Trying to change a parent’s mind is a stronger action that could be more effective than other 
actions (e.g., giving more information or offering to talk at a later visit). For each model, the 
direction and statistical significance of findings remained the same. Thus, we do not report 
further on these analyses. 
Results 
Adolescent and Parent Characteristics 
The majority of parents were non-Hispanic white (71%) and had an annual household 
income of at least $75,000 (61%) (Table 6.1). Less than half had an education of college or more 
(47%). Our sample included parents from all US regions. 
Provider Response During the Visit 
More than one-third of parents received any active response from their provider after 
declining HPV vaccination (35%; Table 6.2), but almost two-thirds indicated that a provider 
should take an active response (61%, p<0.01, Figure 6.1). Compared to those that received the 
response, more parents wanted providers to talk about HPV vaccination at a later visit (21% vs. 
34%), give more information (12% vs. 38%), or ask the parent to sign a form confirming they 
refused to vaccinate (1% vs. 8%, all p<.01). In contrast, fewer parents wanted a provider to try to 
change their minds (8% vs. 3%, p<0.01).  
Provider Follow-up After the Visit 
Over one-third of parents who declined HPV vaccination received follow-up from the 
provider after the visit (39%). Overall, more parents (68%) reported that a provider should 
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follow-up after the visit when parents decline HPV vaccination (p<.01). Compared to those that 
received the response, more parents suggested a provider should bring HPV vaccination up again 
at the next visit (34% vs. 58%, Figure 6.2), send a reminder (4% vs. 11%), and schedule another 
visit to talk about vaccination (4% vs. 8%, all p<.01).  
Negative Affect and Discomfort with the Visit 
Only a minority of parents reported feeling any discomfort (11%) or negative decisional 
affect (38%) during the visit. Parents most commonly reported feeling unsure (29%), followed 
by uncomfortable (12%), worried (9%), and annoyed (5%).  
Correlates of Secondary Acceptance 
Overall, 29% of parents who initially declined HPV vaccination later vaccinated their 
child. Parents had higher odds of secondary acceptance if they received any follow-up from a 
provider (43% vs. 20%, aOR:3.19; 95% CI:2.00:5.07; Table 6.3), controlling for adolescent and 
parent characteristics. Receipt of an active response from a provider and negative decisional 
affect were not associated with odds of secondary acceptance. Discomfort with a provider was 
associated with lower odds of secondary acceptance (aOR:0.50; 95% CI:0.34:0.72). 
Discussion 
Our national study found that only about one-third of parents received an active response 
to HPV vaccination declination during their visit or follow-up after their visit. Follow-up after 
the visit (i.e., scheduling another visit, bringing it up again at the next visit, or sending a 
reminder) was associated with secondary acceptance, although an active response from a 
provider was not. More parents wanted an active response and follow-up compared to those that 
actually received them. Finally, relatively few parents experienced discomfort during the visit or 
negative decisional affect.  
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Our study suggests that follow-up after the visit may be a crucial time for intervention to 
increase HPV vaccination coverage. For most parents, follow-up consisted of the provider 
discussing HPV vaccination at the next visit. This finding adds to an earlier study that found that 
follow-up counseling at a later visit was associated with increased odds of secondary 
acceptance.12 Aligned with the Increasing Vaccination Model,28 the provider follow-up actions 
we measured (i.e., discussing vaccination at the next check-up, scheduling another visit, or 
sending a reminder) may have been an effective way to directly change behavior by cuing 
parents with existing favorable intentions to vaccinate. The additional follow-up may have re-
emphasized the importance of vaccination while also respecting parents’ wish for more time to 
think about the vaccine. Indeed, the vast majority of those who later vaccinated (98%) were 
parents who initially delayed, rather than refused, vaccination. This suggests that an additional 
cue to action may be effective for parents who are hesitant, but not completely opposed, to 
vaccination.  
Notably, we did not observe an increase in secondary acceptance from an active response 
during the visit. Some of the provider active responses may have been attempting to change 
parents’ thoughts and feelings, which has shown less promise than attempts to directly intervene 
on behavior.47 Providers may not be responding effectively enough to change thoughts and 
feelings and therefore increase secondary acceptance. Providers often respond to parental 
requests to delay HPV vaccination in a manner that suggests vaccination is optional and not 
urgent97 or that gives parents permission to delay HPV vaccination.98 Thus, providers who 
engage in active response (e.g., giving more information, offering to talk at a later visit) may also 
be inadvertently using language that diminishes the vaccine’s importance. Alternately, providers 
who were too assertive may have inadvertently caused reactance, in which people act in 
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opposition to health messages as a means of retaining control.99 Several promising 
communication techniques to address vaccine hesitant parents exist, including motivational 
interviewing, although none have yet been evaluated in isolation from multicomponent HPV 
vaccination interventions.28,100  
Our findings also suggest that parents who initially decline would like providers to 
respond and follow-up more often than they actually do. A higher proportion of parents endorsed 
“giving more information” and “follow-up at the next visit” as actions a provider should take 
compared with the proportion of parents that reported their provider took those actions. These 
findings suggests that many parents are open and receptive to additional response and follow-up 
from providers when they decline HPV vaccination. The American Academy of Pediatrics 
(AAP) recommends that providers encountering parental declination should listen respectfully to 
parents to understand their concerns and engage in non-confrontational dialogue about vaccine 
safety and the risks and benefits of immunization.101 The AAP also notes that providers can give 
more information or ask the parents to sign a waiver at the provider’s discretion. Our study 
suggests that providers infrequently engage in these actions, with most parents reporting that 
their provider did not engage in any type of active response during the visit or follow-up after the 
visit. The low proportion of providers engaging in active response and follow-up is striking, 
given that almost all pediatricians report encountering parents hesitant about vaccination.102  
Our study also examined the role of negative decisional affect and discomfort during the 
visit in parental declination. Few parents reported experiencing negative decisional affect or 
discomfort with the visit. The most common negative decisional affect item reported was feeling 
unsure, which could potentially indicate that parents were appropriately contemplating a 
provider’s advice. Stronger negative decisional affect, such as worried or annoyed, were less 
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commonly reported. The infrequency of strong negative decisional affect and discomfort with 
the visit among parents should ease concerns that providers frequently report about the potential 
for confrontational, time-consuming conversations surrounding HPV vaccination due to parents’ 
opposition.44,103  
Our study points to several areas for future research. Future studies should examine 
whether specific aspects of a provider’s active response (e.g., specific messages) or follow-up are 
more successful than others at increasing secondary acceptance. In our sample, few parents 
received reminders or had an additional visit scheduled to talk about vaccination. Understanding 
whether these specific actions are effective would identify specific, actionable strategies that 
providers can use to increase secondary acceptance. Reminders for HPV vaccination have shown 
some promise at increasing HPV vaccination initiation and completion in clinical trials, 
suggesting that it may also be a useful strategy for parents who decline HPV vaccination.104-106 
Future research could also examine whether concordance between a provider’s response to HPV 
vaccination declination and a parents’ preferred response could increase secondary acceptance.  
Strengths of this study include a national sample and a focus on a novel and understudied 
aspect of HPV vaccination (provider response to HPV vaccination declination). The major 
limitation of this study is the cross-sectional design which precludes assertations regarding 
causal inference. Although surveying parents for their affect and response to a patient-provider 
conversation separately from the conversation may not be possible, measuring whether change in 
the outcome came after the patient-provider conversation would strengthen our findings. 
Additionally, the self-reported nature of HPV vaccination status and parents’ decision during the 
first conversation is subject to recall bias. Depending on a child’s age, the initial discussion could 
potentially have occurred several years prior to the survey, and parents may not accurately recall 
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their initial decision as well as the emotions and comfort with the provider. Likewise, although 
self-report of HPV vaccination initiation is fairly reliable,107 it could be subject to recall bias, 
especially for some racial and ethnic groups.39 Finally, for the provider active response and 
provider follow-up variables, parents could have selected “none of these” if their provider 
engaged in another response or follow-up action that was not listed on the survey. For several 
negative decisional affect items (e.g., worry or fear), we do not know whether parents felt the 
negative affect concerning vaccination (e.g., worried about the harms of vaccination) or 
concerning the failure to vaccinate (e.g., worry about their child getting cancer). 
Conclusions 
HPV vaccination declination is a pressing public health problem. Our study underscores 
the urgent need to understand how providers can effectively communicate with parents who 
decline HPV vaccination. The majority of parents who decline do not receive active response 
during the visit or follow-up after the visit, although they are receptive to such actions and rarely 





Table 6.1. Sample characteristics, United States, 2017 (n=447) 
 n (%) 
Adolescent characteristics   
Sex at birth   
Male 218 (49) 
Female 229 (51) 
Age (years)   
9-10 74 (17) 
11-12 116 (26) 
13-14 105 (23) 
15-17 152 (34) 
HPV vaccination status   
0 doses 318 (71) 
1 dose 129 (29) 
Parent characteristics   
Gender   
Male 193 (43) 
Female 254 (57) 
Education   
Some college or less 238 (53) 
College or more 209 (47) 
Race/ethnicity   
Non-Hispanic White 321 (71) 
Non-Hispanic Black 43 (10) 
Hispanic 49 (11) 
Non-Hispanic, Other or Multiple race  34 (8) 
Household characteristics   
Annual income   
$0-$34,999 64 (14) 
$35,000-$74,999 109 (24) 
≥$75,000 274 (61) 
Region   
Northeast 70 (16) 
Midwest 119 (27) 
South 157 (35) 





Table 6.2. Visit characteristics, United States, 2017 (n=447) 
 n (%) 
Provider response to declining the vaccine   
Active Response 156 (35) 
Offer to talk about the HPV vaccine again at a later visit 95 (21) 
Give you more information 52 (12) 
Try to change your mind 37 (8) 
Ask you to sign a form confirming that you refuse to vaccinate 6 (1) 
No active response 291 (65) 
Accept your decision 240 (54) 
Move on with the visit without much comment 85 (19) 
None of these 68 (15) 
Effect on visit   
Much less comfortable 10 (2) 
Somewhat less comfortable 40 (9) 
Neither more nor less comfortable 350 (78) 
Somewhat more comfortable 31 (7) 
Much more comfortable 16 (4) 
Decisional affect   
Negative 171 (38) 
Unsure 130 (29) 
Uncomfortable 52 (12) 
Worried 42 (9) 
Annoyed 22 (5) 
Positive or other 276 (62) 
Confident 131 (29) 
At ease 98 (22) 
Relieved 8 (2) 
Optimistic 36 (8) 
None of these 54 (12) 
Provider follow-up   
Scheduling another visit to talk about it again 20 (4) 
Bringing it up again at the next check-up 151 (34) 
Sending a reminder (by phone, text, email, or mail) 16 (4) 
None of these 273 (61) 
Secondary Acceptance of HPV Vaccination1   
Yes 129 (29) 
No 318 (71) 




Table 6.3. Associations of active provider response and provider follow-up with secondary 
acceptance (n=447) 




 Secondary acceptance 
 n/N (%) OR (95% CI) aOR (95% CI) 
Active provider response       
No 81/291 (28) 1.00 -- 1.00 -- 
Yes 48/156 (31) 1.15 (0.75:1.76) 0.97 (0.60:1.57) 
Provider follow-up       
No 55/273 (20) 1.00 -- 1.00 -- 
Yes 74/174 (43) 2.93 (1.92:4.47)** 3.00 (1.89:4.76)** 
Provider recommendation       
No 28/143 (20) 1.00 -- 1.00 -- 
Yes 101/304 (33) 2.04 (1.27:3.30)* 2.24 (1.32:3.77)* 
Discomfort with provider -- -- 0.55 (0.39:0.77)** 0.50 (0.34:0.72)** 
Negative decisional affect       
No 79/276 (29) 1.00 -- 1.00 -- 
Yes 50/171 (29) 1.03 (0.68:1.57) 1.09 (0.68:1.74) 
Child age -- -- 1.05 (0.97:1.14) 1.00 (0.91:1.09) 
Child sex at birth       
Male 57/218 (26) 1.00 -- 1.00 -- 
Female 72/229 (31) 1.30 (0.86:1.96) 1.10 (0.71:1.72) 
Parent education       
Some college or less 73/238 (31) 1.00 -- 1.00 -- 
College or more 56/209 (27) 0.83 (0.55:1.25) 0.72 (0.44:1.19) 
Annual household income -- -- 1.02 (0.97:1.07) 1.04 (0.97:1.10) 
Parent race/ethnicity       
Non-Hispanic White 84/321 (26) 1.00 -- 1.00 -- 
Non-Hispanic Black 17/43 (40) 1.85 (0.95:3.57) 1.48 (0.71:6.26) 
Hispanic 12/49 (25) 0.92 (0.46:1.84) 0.93 (0.77:1.12) 
Multiple/other 16/34 (47) 2.51 (1.22:5.14)** 2.86 (1.31:6.26)* 
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Figure 6.1. Providers' response to HPV vaccination declination during the visit vs. parents' 
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Figure 6.2. Provider follow-up to HPV vaccination declination after the visit vs. parents’ 
preferred follow-up, *p<0.01 
 






























CHAPTER SEVEN. DISCUSSION 
This dissertation examined two understudied aspects of provider communication related 
to HPV vaccination: geographic disparities in provider recommendations and provider response 
to parental declination.  In Aim 1 and 2, I examined immunization jurisdiction and adolescent 
characteristics associated with receipt of a provider recommendation and HPV vaccination in a 
multilevel context. I used Andersen’s Model of Healthcare Utilization to identify predisposing 
and enabling jurisdiction characteristics.37 This study found that adolescents less often received a 
provider recommendation if their jurisdiction did not have Medicaid expansion or had higher 
poverty rates. Adolescents less often initiated HPV vaccination if they lived in jurisdictions 
where provider recommendations were relatively uncommon or without universal VFC 
programs. Aim 3 assessed associations between providers’ response and follow-up to HPV 
vaccination declination and parents’ secondary acceptance of HPV vaccination. This study found 
that follow-up after the visit was associated with higher odds of secondary acceptance, but an 
active response from a provider was not. Further, parents indicated that they wanted providers to 
actively respond and follow-up more often than providers actually did. Next, I describe 
overarching themes across chapters, future directions for research, and strengths and limitations 
of these studies. 
Aim 1 and 2 Conclusions 
Geography is associated with whether an adolescent receives a provider recommendation 
This study demonstrated the importance of geography in provider recommendations. This 
study found that immunization jurisdictions explain a small but noteworthy amount of variation 
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in provider recommendations (4%).  To the best of my knowledge, no studies have examined 
potential geographic correlates of provider recommendations in a multilevel context, although a 
wide body of research examines how individual characteristics are associated with receipt of a 
provider recommendation 5-9 and several studies have descriptively reported geographic variation 
in provider recommendations.3,14 This study provided an estimate of the extent to which living in 
a certain jurisdiction exerts an effect on an adolescent’s odds of HPV vaccination. This study 
adds to existing literature that examines geographic variation in HPV vaccination in multilevel 
contexts16,29,30,78 by demonstrating the multilevel nature of an important correlate of HPV 
vaccination. 
Jurisdiction-level provider recommendations correlate with HPV vaccination uptake. 
As hypothesized, adolescents living in jurisdictions with higher proportions of provider 
recommendations more often initiated HPV vaccination, above and beyond an individual’s 
receipt of a recommendation. This finding aligns with one ecological study that found states’ 
average proportions of provider recommendations correlated with states’ HPV vaccination 
coverage.14 Possibly, jurisdictions with higher proportions of provider recommendations shared 
important characteristics, such as positive provider norms or greater availability of healthcare 
providers, that facilitate an adolescent’s receipt of a provider recommendation.  
State public health programs and policies are important jurisdictional characteristics associated 
with receipt of a provider recommendation and HPV vaccination initiation. 
Aim 1 and 2 identified jurisdiction enabling characteristics of Medicaid expansion and 
the VFC program that are associated with odds of a provider recommendation and HPV 
vaccination. In contrast with a prior study,16 I found no association between Medicaid expansion 
and HPV vaccination initiation, although Aim 1 demonstrated that adolescents less often 
received provider recommendations if they lived in Medicaid expansion jurisdictions. Universal 
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VFC programs were associated with HPV vaccination initiation at the jurisdiction and adolescent 
level, which aligns with prior research demonstrating higher HPV vaccination coverage in 
universal VFC states.38 Universal VFC programs reduce providers’ financial barriers, such as the 
upfront cost to purchase HPV vaccine and low reimbursement rates.76,92,108-110 Universal VFC 
programs may have also reduced cost barriers among parents.110  
Implications 
This study demonstrated opportunities to better target intervention efforts by geography.  
Some geographic areas may benefit from provider communication interventions more than 
others. While Rhode Island and Massachusetts have achieved higher saturation in provider 
recommendations, jurisdictions such as Mississippi and Wyoming still could benefit from 
evidence-based interventions to improve provider recommendations.28,100 This study also 
highlighted jurisdiction characteristics that may be important to consider when delivering 
provider communication interventions. Areas with lower proportions of provider 
recommendations may have different healthcare infrastructure (e.g., less expansive VFC 
programs) that require tailored or more intensive interventions.  
Future Directions for Research 
These two studies raise several ideas for future research.  First, spatial regression analysis 
could provide further understanding of geographic patterns in HPV vaccination. Our study used a 
multilevel model to correct for jurisdiction correlation and to further understand the impact of 
jurisdiction-specific variables (e.g., VFC program type) on provider communication and HPV 
vaccination. However, multilevel modeling rests on the assumption that correlations between 
jurisdictions are independent. Spatial regression may provide a more nuanced and refined 
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understanding of how HPV vaccination differs by geography by modeling the spatial distribution 
of HPV vaccination.111  
Second, we could study VFC program and Medicaid expansion over time to understand 
whether changes in these health programs and policies have led to changes in jurisdictions’ HPV 
vaccination coverage. Jurisdictions frequently change whether they offer universal coverage 
based on available funding, and this change could be associated with changes in HPV 
vaccination or provider recommendations. Although a randomized control trial is unfeasible for 
examining the effectiveness of policy, studying the associations between VFC program type and 
provider recommendations and HPV vaccination coverage over a longer period of time could 
provide more robust evidence of a causal link by demonstrating whether changes to VFC 
program type consistently precede changes in likelihood of HPV vaccination. Thus, using NIS-
teen and VFC program and Medicaid expansion data in a repeated cross-sectional analysis that 
incorporates a multilevel design could highlight associations over time that may not have been 
apparent in the years we assessed.  
Finally, studying VFC program characteristics could identify whether a program’s reach, 
training, or budget may be associated with provider recommendations or HPV vaccination.  As 
previously noted, the VFC program may play an important role in whether providers recommend 
HPV vaccination in ways that were not measured in this study. Perhaps, it is less important that a 
program provides access to more adolescents and more important that it enrolls a high proportion 






Aim 3 Conclusions 
Provider follow-up is important to secondary acceptance among parents who decline HPV 
vaccination 
In Aim 3, our study demonstrated that provider follow-up correlates with secondary 
acceptance among parents who decline HPV vaccination. This finding emphasizes the 
importance of engaging with parents who decline HPV vaccination after the visit to increase 
secondary acceptance. Additional follow-up after the visit could be an effective way to directly 
change parents’ behavior by keeping vaccination at the forefront of their mind. This finding also 
underscores the importance of providers recommending HPV vaccination on-time in order to 
have more opportunities to speak with hesitant parents. With the nationwide rollout of COVID-
19 vaccines, encouraging on-time HPV vaccination is more crucial than ever, as provider orders 
of HPV vaccine decreased substantially during the COVID-19 pandemic.1  
This study also provides some reassuring news for providers with concerns about 
engaging parents who decline HPV vaccination. Few parents who declined HPV vaccination 
reported experiencing discomfort with the provider and/or negative decisional affect. In addition, 
most parents reported that a provider should actively respond or follow-up when a parent 
declines HPV vaccination, although few received such actions. Together, these findings suggest 
that many parents who decline will be receptive to additional discussion or follow-up action from 
a provider. 
Implications 
This study provides direction to providers about how to increase secondary acceptance. 
Our findings suggest that follow-up after the visit can be a useful strategy to increase secondary 
acceptance. Additional research is needed to understand how parents can effectively respond to 
parental declination during the visit. 
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Future Directions for Research 
Future research should assess how providers can more effectively encourage parents who 
decline HPV vaccination to later accept. Conducting research with a larger sample would allow 
us to examine associations between each specific response (e.g., giving the parent more 
information) and follow-up action (e.g., sending a reminder) to determine what specific actions 
were most effective at increasing secondary acceptance.  
This study also highlights the urgent need to identify effective communication strategies 
to increase secondary acceptance. Two studies have highlighted potential communication 
strategies to address parental declination of HPV vaccination. First, a provider communication 
intervention for HPV vaccination used a structured approach to identify and ease parents’ 
concerns.28 A second multicomponent provider communication intervention used a motivational 
interviewing approach with hesitant parents.100 Both studies focused on how to initially 
recommend HPV vaccine to parents and used these strategies with parents who had additional 
questions or concerns. Studying these interventions specifically within the context of HPV 
vaccination declination could build evidence-based communication strategies that increase 
secondary acceptance.  
Strengths and Weaknesses 
Strengths of this dissertation include the use of two large, national samples for both aims. 
Aims 1 and 2 use a national probability sample, while Aim 3 uses a national sample. Aim 2 also 
benefits from a provider-verified outcome of HPV vaccination. The use of a multilevel model, an 
underutilized but important analytic technique, is a strength of this dissertation. Multilevel 
research is particularly informative for this study because it quantifies the extent to which 
geographic place of residence (e.g., state) contributes to an individual’s overall likelihood of 
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receiving a provider recommendation. Likewise, it offers the ability to determine the relative 
contribution of geographic versus individual characteristics in determining an individual’s 
likelihood of receiving a provider recommendation or HPV vaccination. Aim 3 includes a novel 
focus on provider communication after parents decline HPV vaccination. 
Weaknesses include a cross-sectional design that precludes causal inference between 
variables. Likewise, the response rate for Aims 1 and 2 was low (26%), which could have led to 
nonresponse bias.48 The NIS-teen sample includes adolescents who are older than the age at 
which on-time HPV vaccination occurs. Measuring HPV vaccination initiation and provider 
recommendations in children ages 11-12 would provide an understanding of the extent to which 
providers are recommending HPV vaccination on-time. The provider recommendation variable 
in NIS-teen only asks whether an adolescent received a provider recommendation but does not 
say when the adolescent received the recommendation. The Aim 1 and 2 sample consisted of 
those adolescents with provider-verified vaccination records. Adolescents with provider-verified 
vaccination records may differ in important characteristics (e.g., higher income, greater 
healthcare use) than adolescents without provider-verified records. The outcome variables for 
Aim 1 and 3, provider recommendation for HPV vaccination and secondary acceptance, were 
self-reported and could be subject to recall bias. In Aim 1 and 2, certain jurisdiction 
characteristics (e.g., VFC Program) could have benefited from more refined measurement. For 
example, the VFC Program may influence provider recommendations and HPV vaccination in 
ways that were not measured in these studies. VFC programs in certain jurisdictions may be 
more successful than others at enrolling providers or at training and communicating with 
providers. VFC Programs also offer provider education and training through IQIP programs;112 
certain jurisdictions may offer more robust training than others, which could account for 
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jurisdiction differences in provider recommendations. Although multilevel modeling is a strength 
of this study, it does have several disadvantages. Notably, multilevel modeling rests on the 
assumption that the highest level (jurisdiction) is free of correlated error terms. In our study, it’s 
possible that some correlation could exist between certain jurisdictions (e.g., Mississippi and 
Alabama) as other studies have found significant regional differences in HPV vaccination 
coverage. However, the low ICC between jurisdictions suggests that broader geographic regions 
are unlikely to be substantially correlated to the extent that associations would be skewed.  
Overall Conclusions 
Provider communication is essential to increasing HPV vaccination coverage. Our study 
demonstrates the importance of considering area-level characteristics may influence provider 
communication for HPV vaccination. I identified area-level characteristics of Medicaid 
expansion and universal VFC programs that are associated with provider recommendations and 
HPV vaccination. This study also provides valuable direction for providers in how to increase 





APPENDIX A: STUDY MEASURES 
Table A.1. Aim 1 and 2 measures  
Variable Item Response Options Coding 
Data 
source 




number of doses of 
HPV vaccine 0, 1, 2, or 3 doses 
1 = Yes [≥1 
dose] 













1 = Yes 
2 = No  
77 = Don't know 
99 = Refused 
1 = Yes [1] 






At this time, does 
[TEEN] have health 
insurance coverage? 
1 = Yes 
2 = No 
77 = Don’t know 
99 = Refused 
1 = Yes [2] 






At this time, what 
kind of health 
coverage does 
[TEEN] have? Any 
other kind? 
1 = Medicaid 
2 = Medicare 
3 = Children’s’ Health 
Insurance Program 
(CHIP)  
4 = Medigap 
5 = Military 
6 = Indian Health 
Service (IHS) 
7 = Private Insurance 
8 = Single Service 
Plan 
9 = Other 
77 = Don’t know 
99 = Refused 
1 = Private [7]a 
2 = Public – 
Non-Medicaid 
[2/3/4/5/6/8/9] 






What is the age of 
the [first/second…] 
child under the age 





Is this child male or 
female? 
1 = Male 
2 = Female 
77 = Don't know 
99 = Refused 
1 = Male [1] 














Please choose one or 
more of the 
following categories 
to describe [TEEN] 
race. 
1 = Hispanic 
2 = Non-Hispanic 
white 
3 = Non-Hispanic 
Black 
4= Non-Hispanic 
Other/Multiple Race  
Hispanic: 
1 = Yes [1] 
0 = No [2] 
Non-Hispanic 
white 
1 = Yes [1] 
0 = No [2] 
Non-Hispanic 
Black 
1 = Yes [1] 




1 = Yes [1] 






What is the highest 
grade or year of 
school [FILL1] 
completed? 
1 = Less than 12 years 
2 = 12 years 
3 = More than 12 
years, non-college 
graduate 
4 = College graduate  
1 = Less than 
college degree 
[1/2/3] 








Please think about 
your total combined 
family income 
during 2015 for all 
members of the 
family. Can you tell 
me that amount 
before taxes? $ [whole number] 



















The number of 
adolescents who 
received a provider 
recommendation 
divided by the total 
number of 
adolescents in a 















as of January 2018 
1 = Non-Medicaid 
expansion 

















VFC, consisting of 
which vaccines are 
supplied by the 
program and to 
which subgroups of 
adolescents the 
vaccines are given 
Universal 
Universal-select  

















Number of residents 
with incomes below 
the Federal poverty 
level divided by the 
total number of 
residents in each 
jurisdiction, as 
estimated by the 







Hispanic residents in 
each jurisdiction 
The number of 
Hispanic residents in a 
jurisdiction divided by 
the total number of 






Proportion of Black 
residents in each 
jurisdiction 
The number of Black 
residents in a 
jurisdiction divided by 
the total number of 











The number of 
residents in a 
jurisdiction living in 
non-MSAs divided by 
the total number of 






Table A.2. Aim 3 measures  






When you decided not 
to get the HPV 
vaccine, did 
[NAME]’s doctor or 
health care provider… 
(Check all that apply) 
1 = Accept your 
decision 
2 = Give you more 
information 
3 = Offer to talk 
about the HPV 
vaccine again at a 
later visit 
4 = Try to change 
your mind 
5 = Ask you to sign a 
form confirming that 
you refuse to 
vaccinate 
6 = Move on with the 
visit without much 
comment 
1 = Active 
response [2/3/4/5]  






When you decided not 
to get the HPV 
vaccine for [NAME], 
did the doctor or 
health care provider 
follow up by… 
(Check all that apply) 
1 = Scheduling 
another visit to talk 
about it again   
2 = Bringing it up 
again at the next 
check-up 
3 = Sending a 
reminder (by phone, 
text, email, or mail) 
4 = None of these 
 
1=Follow-up after 
the visit [1/2/3] 
0= No follow-up 





How many shots of 
the HPV vaccine has 
[NAME] had? 
0 = None 
1 = 1 shot 
2 = 2 shots 
3 = 3 or more shots 
4 = At least 1 shot, 
but I don’t know how 
many 
5 = I don’t know if 
my child has received 
the HPV vaccine 
Among parents 




be coded as: 
1 = 1 shot [1/4] 
0 = None [0/5] 
 
Note: Parents 
who responded 2 
or 3 were 










with the visit 
How did your 
conversation about the 
HPV vaccine affect 
that visit with 
[NAME]’s doctor or 
health care provider? 
Did it make the visit… 
1 = Much less 
comfortable 
2 = Somewhat less 
comfortable 
3 = Neither more or 
less comfortable 
4 = Somewhat more 
comfortable 




5 = Much less 
comfortable 
4 = Somewhat 
less comfortable 
3 = Neither more 
or less 
comfortable 
2 = Somewhat 
more comfortable 







At that visit, how did 
you feel about your 
HPV vaccine 
decision? 
(Check all that apply) 
1 = Worried 
2 = Unsure 
3 = Annoyed 
4 = Uncomfortable 
5 = At ease 
6 = Confident 
7 = Relieved 
8 = Optimistic 
9 = None of these 
1 = Negative 
affect [1/2/3/4] 




Child age How old is [NAME]? 
1 = 9 years old 
2 = 10 years old 
3 = 11 years old 
4 = 12 years old 
5 = 13 years old 
6 = 14 years old 
7 = 15 years old 
8 = 16 years old 
9 = 17 years old 
0 = 9 years old 
1 = 10 years old 
2 = 11 years old 
3 = 12 years old 
4 = 13 years old 
5 = 14 years old 
6 = 15 years old 
7 = 16 years old 





What is [NAME]’s 
race or ethnicity? 
(Check all that apply.) 
1 = White, Non-
Hispanic   
2 = Black, Non-
Hispanic   
3 = Other, Non-
Hispanic   
4 = Hispanic   
5 = 2+ Races, Non-
Hispanic 
 
1 = Non-Hispanic 
White [1] 
2 = Non-Hispanic 
Black [2] 
3 = Hispanic [4] 
4 = Other [3/5] 
SIP 
survey113 
Child's sex at 
birth 
What was [NAME]’s 
sex at birth? 
1 = Male 
2 = Female 
1 = Male [1] 










Variable provided by 
survey company 
1 = 'No formal 
education'   
2 = '1st, 2nd, 3rd, or 
4th grade'   
3 = '5th or 6th grade'   
4 = '7th or 8th grade'   
5 = '9th grade'   
6 = '10th grade'   
7 = '11th grade'   
8 = '12th grade no 
diploma   
9 = ‘High School 
Graduate’ - high 
school diploma or the 
equivalent (GED)'   
10 = 'Some college, 
no degree'   
11 = 'Associate 
degree'   
12 = 'Bachelors’ 
degree'   
13 = 'Masters’ degree'  
14 = 'Professional or 
Doctorate degree'  
1 = College and 
above [12/13/14] 
0 = Some college 
or below 
[1/2/3/4/5/6/7/8/9/






Variable provided by 
survey company 
1 = 'Less than $5,000'   
2 = '$5,000 to $7,499'   
3 = '$7,500 to $9,999'   
4 = '$10,000 to 
$12,499'   
5 = '$12,500 to 
$14,999'   
6 = '$15,000 to 
$19,999'   
7 = '$20,000 to 
$24,999'   
8 = '$25,000 to 
$29,999'   
9 = '$30,000 to 
$34,999'   
10 = '$35,000 to 
$39,999'   
11 = '$40,000 to 
$49,999'   
3 = Low ($0-
$74,999) [1-13] 
2 = Medium 
($75,000-
$149,999) [14-17] 







Variable Item  Response Option  Coding 
 Data 
source 
12 = '$50,000 to 
$59,999'   
13 = '$60,000 to 
$74,999'   
14 = '$75,000 to 
$84,999'   
15 = '$85,000 to 
$99,999'   
16 = '$100,000 to 
$124,999'    
17 = '$125,000 to 
$149,999'   
18 = '$150,000 to 
$174,999'   
19 = '$175,000 to 
$199,999'   
20 = '$200,000 to 
$249,999'   





APPENDIX B: CROSS LEVEL INTERACTION BETWEEN MEDICAID EXPANSION 
AND PROVIDER RECOMMENDATION 
Data Analysis 
For the significant interaction between Medicaid expansion and adolescent receipt of 
provider recommendation, we probed the interaction in post-hoc analysis to determine the 
direction and strength of the association. We ran a series of estimate statements in PROC 
GLIMMIX to assess associations between receipt of a provider recommendation and HPV 
vaccination depending on whether the adolescent lived in a Medicaid expansion jurisdiction or 
non-Medicaid expansion jurisdiction. Because we group-mean centered receipt of a provider 
recommendation, we also included the group mean (proportion of provider recommendations) in 
the interaction. Group mean-centering the provider recommendation variable transforms it into a 
deviation from the jurisdiction average (the jurisdiction’s proportion of provider 
recommendations). Thus, we included the group mean to facilitate interpretation of the group 
mean centered variable (receipt of a provider recommendation).  We ran separate estimate 
statements for adolescents who lived in jurisdictions with low proportions of provider 
recommendations (1 standard deviation below the average proportion of provider 
recommendations), average proportions of provider recommendations, and high proportions of 
provider recommendations (1 standard deviation above the mean).   
Results 
The interaction between Medicaid expansion and receipt of a provider recommendation 
was significant (aOR:1.48; 95% CI:1.20:1.82; Table B.1). Among adolescents who did not 
receive a provider recommendation, those that lived in jurisdictions without Medicaid expansion 
had lower odds of HPV vaccination initiation compared with those that lived in jurisdictions with 
Medicaid expansion.  This trend was observed among adolescents living in low provider 
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recommendation jurisdictions (39% vs. 49%, aOR:0.66; 95% CI:0.53:0.82), average provider 
recommendation jurisdictions (43% vs. 54%, aOR:0.64; 95% CI: 0.51:0.80), and high provider 
recommendation jurisdictions (47% vs. 58%, aOR:0.63; 95% CI:0.50:0.79). Among adolescents 
that received a provider recommendation, there was no significant difference between those that 
lived in Medicaid expansion jurisdictions and those that lived in non-Medicaid expansion 
jurisdictions. This association was observed among adolescents in low provider recommendation 
jurisdictions (aOR:0.98; 95% CI:0.83:1.16), average provider recommendation jurisdictions 









    
 
 
Table B.1. Associations between adolescent and immunization jurisdiction characteristics and HPV vaccination initiation 
HPV vaccination 
initiation/
Total adolescents (%)1 OR (95% CI) aOR (95% CI) 
     
 Immunization Jurisdiction     
 Proportion of Provider 
Recommendations 
-- -- 1.56 (1.35:1.80)** 1.54 (129:1.83)** 
 Universal VFC program     
 Yes (ref) 2,180/2,922 (77) 1.00 --   1.00 -- 
 No 6,674/14,329 (68) 0.72 (0.54:0.84)** 0.82 (0.66:1.03) 
 Medicaid expansion       
 Yes (ref)  7,255/10,045 (71) 1.00    1.00 -- 
 No 4,651/7,206 (64) 0.67 (0.55:0.82)** 0.87 (0.74:1.02) 
 Poverty rate -- -- 0.91  (0.66:1.26) 1.43 (1.03:1.99)* 
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Proportion of Hispanic residents -- -- 1.00 (0.99:1.01) 1.00 (0.99:1.01) 
Proportion of Black residents  -- -- 1.01  (1.00:1.02) 1.00 (0.99:1.01) 
 Proportion of rural residents 0.99 (0.98:1.00) 0.99 (0.99:1.00) 
 Adolescents    
 Receipt of provider recommendation2      
 No (ref) 1,681/3,692 (46) 1.00 -- 1.00 -- 
 Yes 10,225/13,559 (75) 3.54 (3.28:3.83)** 2.94 (2.56:3.37)** 
 Medicaid Expansion*Provider 
recommendation 
-- -- -- -- 1.48 (1.20:1.82)** 
 Age --  -- 1.07 (1.05:1.10)* 1.09 (1.06:1.12)** 
 Gender     
 Female (ref) 5,928/8,287 (70) 1.00 -- 1.00 -- 
 Male 5,978/8,964 (67) 0.80 (0.75:0.85)* 0.90 (0.84:0.96)** 
 Maternal education      
 College degree or greater (ref) 5,745/9,034 (68) 1.00 -- 1.00 -- 
 Some college or less 6,161/9,034 (69) 0.99 (0.93:1.01) 0.87 (0.80:0.94)** 






Total adolescents (%)1 OR (95% CI) aOR (95% CI) 
 Insurance status      
 Private (ref) 6,587/9,747 (66) 1.00 -- 1.00 -- 
 Medicaid 3,922/5,350 (74) 1.43 (1.34:1.54)* 1.30 (1.17:1.44)** 
 Uninsured 422/684 (57) 0.76 (0.66:0.89)** 0.94 (0.78:1.12) 
 Other 975/1,470 (65) 1.09 (0.98:1.21)** 1.11 (0.98:1.27) 
 Race/ethnicity       
 Non-Hispanic White 6,877/10,476 (64) 1.00 -- 1.00 -- 
 Hispanic 2,722/3,595 (75) 1.74 (1.59:1.90)** 1.99 (1.77:2.23)** 
 Non-Hispanic Black 999/1,350 (73) 1.27 (1.12:1.44)** 1.54 (1.36:1.73)** 
 Non-Hispanic other/multiple race 1,308/1,830 (66) 1.09 (0.98:1.21) 1.26 (1.12:1.43)** 
106 
Recent doctors’ visit (in past year)       
Yes (ref) 10,592/14,993 (70) 1.00 -- 1.00 -- 
No 1,314/2,258 (61) 0.58 (0.53:0.63)** 0.65 (0.59:0.71)** 
Provider participated in VFC       
Yes (ref) 9,290/13,109 (71) 1.00  -- 1.00 -- 
 No 2,616/4,142 (62) 0.69 (0.65:0.75)** 0.77 (0.71:0.83)** 
 AIC   22,904.96 -- 19,311.21 -- 
 BIC   22,909.01 -- 19,361.85 -- 
 ICC   0.04 -- -- -- 




APPENDIX C: EXPLORATORY MEDIATION ANALYSIS 
Data Analysis 
This exploratory analysis used a multilevel structural equation model (SEM) to analyze 
whether receipt of a provider recommendation acted as a mediator between adolescent and 
jurisdiction characteristics and HPV vaccination initiation (see Figure B.1). SEM offers distinct 
advantages over traditional multilevel regression models in that multilevel SEM allows for 
simultaneous estimation of all pathways in an equation while also examining between and within 
cluster effects.58 As appropriate for a multilevel mediation model with a binary outcome, we first 
ran the model using robust weighted least squares (WLS) to obtain absolute fit statistics.60 We 
used the following absolute fit statistic to determine whether the model adequately fit the sample 
data: Root Mean Square Error of Approximation (RMSEA) less than 0.08;61,62 Standardized 
Root Mean Square Residual (SRMR) less than 0.08;63,64 and, Bentler Comparative Fit Index 
(CFI) greater than 0.95.65 
After determining model fit, we ran the model using maximum likelihood estimation to 
examine whether receipt of a provider recommendation mediates associations between 
adolescent variables and jurisdiction variables.  The following jurisdiction variables were 
identified based on prior research: VFC program type,38 Medicaid expansion,16 the proportion of 
Hispanic residents,30 proportion of Black residents,30 poverty rate,41 and the proportion of rural 
residents.3 The following adolescent variables were identified based on prior research: age,35 
gender,25,35 maternal education,26 household income-to-poverty ratio,25,35 race/ethnicity,6,25-27 
insurance type,27 whether the adolescent saw a VFC provider,87 and whether the adolescent had a 
recent doctors’ visit.27 We then examined the direct effects of adolescent and jurisdiction 
characteristics on HPV vaccination initiation and the indirect effects through provider 
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recommendations as a mediator. To test the indirect effects, we used bootstrapping to obtain 95% 
confidence intervals.68 
Results 
The proposed multilevel mediation model displayed poor initial fit (Figure C.1; 
CFI:0.995, TLI:0.844, RMSEA:0.02, SRMR (within):0.00, SRMR [between]:0.221). Because 
the SRMR for the between-jurisdiction model displayed poor fit, we eliminated non-significant 
pathways with jurisdiction variables and receipt of a provider recommendation or HPV 
vaccination one-by-one until adequate model fit was achieved (CFI:0.99, TLI:0.95, 
RMSEA:0.01, SRMR [within]:0.00, SRMR [between]: 0.04). We also removed non-significant 
mediated pathways between VFC program type, proportion of Black residents, and proportion of 
Hispanic residents and receipt of a provider recommendation and removed proportion of rural 
residents from the model completely. Thus, the final model examined whether receipt of a 
provider recommendation mediated associations between Medicaid expansion and poverty rates 
and HPV vaccination.  
In the multilevel mediation model, receipt of a provider recommendation partially 
mediated the negative association between living in a jurisdiction without Medicaid expansion 
and HPV vaccination (a*b path: 0.74; 95% CI:0.61:0.90) (Table C.1; Figure C.2). After 
controlling for the mediated pathway, living in a jurisdiction without Medicaid expansion 
remained significantly associated with HPV vaccination (c pathway: aOR:0.75; 95% 
CI:0.63;0.90). Similarly, receipt of a provider recommendation fully mediated the pathway 
between living in a jurisdiction with higher poverty rates and HPV vaccination (a*b path:0.58; 
95% CI:0.44:0.75). After controlling for the mediated pathway, living in a jurisdiction with 
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higher poverty rates was not associated with odds of HPV vaccination (c pathway: aOR:0.78; 
95% CI:0.58:1.07).  
At the adolescent level, receipt of a provider recommendation partially mediated 
associations between male gender, lower maternal education, being uninsured, and not having a 
recent doctors’ visit and lower odds of HPV vaccination.  Receipt of a provider recommendation 





Figure C.1. Proposed model of associations between jurisdiction and adolescent characteristics 







Figure C.2. Provider recommendation as a mediator between select jurisdiction characteristics 
and HPV vaccination initiation.  
Note: associations for remaining jurisdiction variables (VFC program type, proportion of Black 
residents, and proportion of Hispanic residents) and adolescent variables (age, gender, maternal 
education, income-to-poverty ratio, insurance status, race/ethnicity, recent doctors’ visit and any 
VFC provider) are displayed in Table 3. *p<0.05 
    
 
 
 Table C.1. Multilevel mediation model of immunization jurisdiction and adolescent characteristics on HPV 
vaccination, mediated through provider recommendations 
  a path  a*b path  c’ path  
  aOR (95% CI) aOR (95% CI) aOR (95% CI) 
 Immunization Jurisdiction       
 Universal VFC program       
 Yes (ref) 1.00 -- 1.00 -- 1.00 -- 
 No -- -- -- -- 0.70 (0.55:0.89) 
 Medicaid Expansion       
 Yes (ref)  1.00 -- 1.00 -- 1.00 -- 
 No 0.80 (0.69:0.93) 0.74 (0.61:0.90) 0.75 (0.63:0.90) 
 Poverty rate 0.66 (0.55:0.81) 0.58 (0.44:0.75) 0.78 (0.58:1.07) 
 Proportion of Black residents -- -- -- -- 1.02 (1.007:1.03) 
 Proportion of Hispanic residents -- -- -- -- 1.01 (1.001:1.02) 
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Adolescents 
      
Provider Recommendation -- -- -- -- 3.86 (3.55:4.19) 
Age 1.03 (1.001:1.06) 1.04 (1.002:108) 1.08 (1.05:1.10) 
Gender       
 Female (ref) 1.00 -- 1.00 -- 1.00 -- 
 Male 0.52 (0.48:0.56) 0.41 (0.37:0.47) 0.91 (0.85:0.98) 
 Maternal education       
 College degree or greater (ref)  1.00 -- 1.00 -- 1.00 -- 
 Some college or less 0.72 (0.65:0.78) 0.64 (0.56:0.72) 0.85 (0.78:0.92) 
 Income-to-poverty ratio 0.82 (0.77:0.86) 0.76 (0.70:0.82) 1.14 (1.07:1.20) 
 Insurance status       
 Private (ref) 1.00 --    1.00 -- 1.00 -- 
 Medicaid 0.84 (0.75:0.95) 0.79 (0.68:0.93) 1.27 (1.13:1.41) 
 Uninsured 0.59 (0.49:0.71) 0.49 (0.38:0.63) 0.90 (0.75:1.09) 
 Other 0.72 (0.62:0.82) 0.63 (0.53:0.77) 1.09 (0.96:1.24) 
 Race       
 Non-Hispanic White 1.00 -- 1.00 -- 1.00 -- 




 Hispanic 0.83 (0.74:0.93) 0.78 (0.67:0.91) 1.97 (1.76:2.20) 
 Non-Hispanic Other/Multiple 
Race 
0.95 (0.84:1.09) 0.94 (0.78:1.12) 1.28 (1.14:1.45) 
 Recent doctors’ visit (in past 
year) 
      
 Yes (ref) 1.00 -- 1.00 -- 1.00 -- 
 No 0.55 (0.50:0.61) 0.45 (0.39:0.52) 0.65 (0.59:0.71) 
 Provider participated in VFC       
 Yes (ref)   1.00 -- 1.00 -- 1.00 -- 
 No 0.87 (0.79:0.95) 0.58 (0.44:0.75) 0.75 (0.69:0.81) 
    Note: path b, the association between provider recommendation and HPV vaccination, was  




APPENDIX D: NEGATIVE DECISIONAL AFFECT CORRELATION 
 
Table D.1. Correlations between negative decisional affect items (n=447)  
  Worried Unsure Annoyed Uncomfortable 
Worried 1.00 0.31** 0.16** 0.43** 
Unsure 0.31 1.00   0.09* 0.29** 
Annoyed 0.16**    0.09*   1.00 0.18** 




1. Elam-Evans LD, Yankey D, Singleton JA, et al. National, Regional, State, and Selected 
Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 
2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1109-1116. 
2. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and 
intraepithelial neoplasia in women. The New England journal of medicine. 2015;372(8):711-
723. 
3. Walker TY, Elam-Evans LD, Yankey D, al. e. National, regional, state, and selected local 
area vaccination coverage among adolescents aged 13–17 years — United States, 2018. 
MMWR Morb Mortal Wkly Rep. 2019;68(33):718-723. 
4. Meites E. Use of a 2-dose schedule for human papillomavirus vaccination—updated 
recommendations of the Advisory Committee on Immunization Practices. MMWR Morb 
Mortal Wkly Rep. 2016;65. 
5. Kessels SJM, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL. Factors 
associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 
2012;30(24):3546-3556. 
6. Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus 
vaccination, and race/ethnicity in the US National Immunization Survey. Am J Public 
Health. 2013;103(1):164-169. 
7. Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider 
communication and HPV vaccination: the impact of recommendation quality. Vaccine. 
2016;34(9):1187-1192. 
8. Reiter PL, McRee A-L, Pepper JK, Gilkey MB, Galbraith KV, Brewer NT. Longitudinal 
predictors of human papillomavirus vaccination among a national sample of adolescent 
males. Am J Public Health. 2013;103(8):1419-1427. 
9. Brewer NT, Gottlieb SL, Reiter PL, et al. Longitudinal predictors of human papillomavirus 
vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis. 
2011;38(3):197-204. 
10. Oh NL, Biddell CB, Rhodes BE, Brewer NT. Provider communication and HPV vaccine 
uptake: A meta-analysis and systematic review. Preventive Medicine. 2021:106554. 
11. HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to 
Action. A Report to the President of the United States from the Chair of the President’s 
Cancer Panel. Bethesda, MD Nov 2018 2018. 
12. Kornides ML, McRee AL, Gilkey MB. Parents Who Decline HPV Vaccination: Who Later 
Accepts and Why? Acad Pediatr. 2018;18(2s):S37-s43. 
 
116 
13. Gilkey MB, Calo WA, Marciniak MW, Brewer NT. Parents who refuse or delay HPV 
vaccine: Differences in vaccination behavior, beliefs, and clinical communication 
preferences. Hum Vaccin Immunother. 2016;13(3):680-686. 
14. Lu PJ, Yankey D, Fredua B, et al. Association of provider recommendation and human 
papillomavirus vaccination initiation among male adolescents aged 13-17 Years-United 
States. The Journal of pediatrics. 2019;206:33-41.e31. 
15. Centers for Disease Control and Prevention. The VFC Program: At A Glance. 2018; 
https://www.cdc.gov/vaccines/programs/vfc/about/index.html. Accessed May 15, 2019. 
16. Hoff BM, Livingston MD, 3rd, Thompson EL. The association between state Medicaid 
expansion and human papillomavirus vaccination. Vaccine. 2020. 
17. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US 
women and men: prevalence and incidence estimates, 2008. Sexually transmitted diseases. 
2013;40(3):187-193. 
18. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. Journal of 
clinical virology : the official publication of the Pan American Society for Clinical Virology. 
2005;32 Suppl 1:S16-24. 
19. Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers - United 
States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661-666. 
20. Robinson CL, Romero JR, Kempe A, Pellegrini C, Szilagyi P. Advisory Committee on 
Immunization Practices recommended immunization schedule for children and adolescents 
aged 18 years or younger - United States, 2018. MMWR Morb Mortal Wkly Rep. 
2018;67(5):156-157. 
21. Healthy People 2030. Immunization and Infectious Disease. 2030; 
https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/increase-
proportion-adolescents-who-get-recommended-doses-hpv-vaccine-iid-08. 
22. American Cancer Society. Our HPV Vaccination Initiatives. 2018; 
https://www.cancer.org/health-care-professionals/hpv-vaccination-information-for-health-
professionals/our-hpv-vaccination-initatives.html. Accessed May 15, 2019. 
23. Centers for Disease Control Prevention. FDA licensure of quadrivalent human 
papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory 
Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 
2010;59(20):630-632. 
24. Jeudin P, Liveright E, del Carmen MG, Perkins RB. Race, ethnicity, and income factors 
impacting human papillomavirus vaccination rates. Clinical Therapeutics. 2014;36(1):24-37. 
 
117 
25. Burdette AM, Webb NS, Hill TD, Jokinen-Gordon H. Race-specific trends in HPV 
vaccinations and provider recommendations: persistent disparities or social progress? Public 
Health. 2017;142:167-176. 
26. Polonijo AN, Carpiano RM. Social inequalities in adolescent human papillomavirus (HPV) 
vaccination: A test of fundamental cause theory. Social Science & Medicine. 2013;82:115-
125. 
27. Lau M, Lin H, Flores G. Factors associated with human papillomavirus vaccine-series 
initiation and healthcare provider recommendation in US adolescent females: 2007 National 
Survey of Children's Health. Vaccine. 2012;30(20):3112-3118. 
28. Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements versus 
conversations to improve HPV vaccination coverage: a randomized trial. Pediatrics. 
2017;139(1):e20161764. 
29. Franco M, Mazzucca S, Padek M, Brownson RC. Going beyond the individual: how state-
level characteristics relate to HPV vaccine rates in the United States. BMC public health. 
2019;19(1):246. 
30. Henry KA, Stroup AM, Warner EL, Kepka D. Geographic factors and human papillomavirus 
(HPV) vaccination initiation among adolescent girls in the United States. Cancer Epidemiol 
Biomarkers Prev. 2016;25(2):309-317. 
31. Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus 
vaccination. Am J Prev Med. 2010;38(5):525-533. 
32. Moss JL, Reiter PL, Truong YK, Rimer BK, Brewer NT. School entry requirements and 
coverage of nontargeted adolescent vaccines. Pediatrics. 2016;138(6):e20161414. 
33. Perkins RB, Lin M, Wallington SF, Hanchate AD. Impact of school-entry and education 
mandates by states on HPV vaccination coverage: analysis of the 2009–2013 National 
Immunization Survey-Teen. Hum Vaccin Immunother. 2016;12(6):1615-1622. 
34. Moss JL, Gilkey MB, Rimer BK, Brewer NT. Disparities in collaborative patient-provider 
communication about human papillomavirus (HPV) vaccination. Hum Vaccin Immunother. 
2016;12(6):1476-1483. 
35. Mohammed KA, Geneus CJ, Osazuwa-Peters N, Boakye EA, Tobo BB, Burroughs TE. 
Disparities in provider recommendation of human papillomavirus vaccination for U.S. 
adolescents. Journal of Adolescent Health. 2016;59(5):592-598. 
36. Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Quality of physician communication 
about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiol 
Biomarkers Prev. 2015;24(11):1673-1679. 
37. Andersen RM, Davidson PL. Improving access to care in America: individual and contextual 
indicators. In: Andersen RM, Rice TH, Kominski G, eds. Changing the U.S. health care 
 
118 
system: Key issues in health services policy and management Vol 2007. San Francisco, CA: 
Jossey-Bass; 2007. 
38. Gowda C, Dempsey AF. Medicaid reimbursement and the uptake of adolescent vaccines. 
Vaccine. 2012;30(9):1682-1689. 
39. Spencer JC, Calo WA, Brewer NT. Disparities and reverse disparities in HPV vaccination: A 
systematic review and meta-analysis. Prev Med. 2019;123:197-203. 
40. Beachler DC, Gonzales FA, Kobrin SC, Kreimer AR. HPV vaccination initiation after the 
routine-recommended ages of 11–12 in the United States. Papillomavirus Research. 
2016;2:11-16. 
41. Pruitt SL, Schootman M. Geographic disparity, area poverty and Human Papillomavirus 
(HPV) vaccination. Am J Prev Med. 2010;38(5):525-533. 
42. Dorell C, Yankey D, Jeyarajah J, et al. Delay and refusal of Human Papillomavirus vaccine 
for girls, National Immunization Survey–Teen, 2010. Clin Pediatr (Phila). 2014;53(3):261-
269. 
43. Gilkey MB, Reiter PL, Magnus BE, McRee AL, Dempsey AF, Brewer NT. Validation of the 
vaccination confidence scale: a brief measure to identify parents at risk for refusing 
adolescent vaccines. Acad Pediatr. 2016;16(1):42-49. 
44. Daley MF, Crane LA, Markowitz LE, et al. Human Papillomavirus vaccination practices: a 
survey of US physicians 18 months after licensure. Pediatrics. 2010;126(3):425-433. 
45. McRee AL, Gilkey MB, Dempsey AF. HPV vaccine hesitancy: findings from a statewide 
survey of health care providers. J Pediatr Health Care. 2014;28(6):541-549. 
46. Kornides ML, Fontenot HB, McRee A-L, Panozzo CA, Gilkey MB. Provider communication 
about HPV vaccination: parents' satisfaction and their vaccination behaviors. Journal of 
Adolescent Health. 2018;62(2):S87. 
47. Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing vaccination: putting 
psychological science into action. Psychol Sci Public Interest. 2018;18(3):149-207. 
48. Centers for Disease Control and Prevention. A User's Guide for the NIS-teen 2018 Public 
Use File. 2019; https://www.cdc.gov/vaccines/imz-managers/nis/downloads/NIS-TEEN-
PUF18-DUG.pdf. Accessed May 1, 2020. 
49. Centers for Disease Control and Prevention. NIS-teen Household Immunization 
Questionnaire. 2018; https://www.cdc.gov/vaccines/imz-managers/nis/downloads/NIS-Teen-
Questionnaire-Q3-2017.pdf. Accessed May 15, 2019. 





51. Association for Immunization Managers (AIM). 2017 AIM Annual Survey Report. Rockville, 
MD2017. 
52. United States Census Bureau. 2010 Census Questionnaire. 2010; 
https://www.census.gov/programs-surveys/decennial-census/technical-
documentation/questionnaires.2010_Census.html. Accessed May 15, 2019. 
53. Foundation KF. Status of State Medicaid Expansion Decisions: Interactive Map. 2019; 
https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-
interactive-map/. 
54. Centers for Disease Control and Prevention. NCHS Urban-Rural Classification Scheme for 
Counties. 2017. 
55. Merlo J, Chaix B, Ohlsson H, et al. A brief conceptual tutorial of multilevel analysis in social 
epidemiology: using measures of clustering in multilevel logistic regression to investigate 
contextual phenomena. Journal of epidemiology and community health. 2006;60(4):290-297. 
56. Snijders T, Bosker RJ, Bosker RJ. Multilevel analysis: an introduction to basic and advanced 
multilevel modeling. Thousand Oaks, CA: Sage Publications, Inc; 1999. 
57. Enders CK, Tofighi D. Centering predictor variables in cross-sectional multilevel models: a 
new look at an old issue. Psychological methods. 2007;12(2):121-138. 
58. Bollen KA. Structural equations with latent variables. Vol 210. New York, NY: John Wiley 
& Sons; 2014. 
59. Preacher KJ, Zyphur MJ, Zhang Z. A general multilevel SEM framework for assessing 
multilevel mediation. Psych Methods. 2010;15(3):209. 
60. Muthén BO. Goodness of fit with categorical and other nonnormal variables. SAGE Focus 
Editions. 1993;154:205-205. 
61. Steiger JH. Structural model evaluation and modification: An interval estimation approach. 
Multivariate Behav Res. 1990;25(2):173-180. 
62. Steiger JH. Understanding the limitations of global fit assessment in structural equation 
modeling. Personality and Individual Differences. 2007;42(5):893-898. 
63. Byrne BM. Structural equation modeling with AMOS, EQS, and LISREL: Comparative 
approaches to testing for the factorial validity of a measuring instrument. International 
Journal of Testing. 2001;1(1):55-86. 
64. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: 
Conventional criteria versus new alternatives. Structural Equation Modeling. 1999;6(1):1-55. 




66. Hooper D, Coughlan J, Mullen M. Structural equation modelling: guidelines for determining 
model fit. Electronic Journal on Business Research Methods. 2008;6(1):2. 
67. Rabe-Hesketh S, Skrondal A, Pickles A. Maximum likelihood estimation of limited and 
discrete dependent variable models with nested random effects. Journal of Econometrics. 
2005;128(2):301-323. 
68. MacKinnon D. Introduction to statistical mediation analysis. New York, NY: Routledge; 
2012. 
69. MacCallum RC, Browne MW, Sugawara HM. Power analysis and determination of sample 
size for covariance structure modeling. Psych Methods. 1996;1(2):130. 
70. American Association for Public Opinion Research. Standard Definitions: Final Dispositions 
of Case Codes and Outcome Rates for Surveys, 9th edition. In: AAPOR, ed2016. 
71. Enders CK. The performance of the full information maximum likelihood estimator in 
multiple regression models with missing data. Educational and Psychological Measurement. 
2001;61(5):713-740. 
72. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination 
decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. 
Clin Pediatr (Phila). 2013;52(2):162-170. 
73. Gilkey MB, Moss JL, McRee A-L, Brewer NT. Do correlates of HPV vaccine initiation 
differ between adolescent boys and girls? Vaccine. 2012;30(41):5928-5934. 
74. Centers for Disease Control and Prevention (CDC). Cancers Associated with Human 
Papillomavirus, United States—2012–2016. Atlanta, GA: Centers for Disease Control and 
Prevention, US Department of Health and Human Services;2019. 
75. Luque JS, Tarasenko Yn Fau - Dixon BT, Dixon Bt Fau - Vogel RL, Vogel Rl Fau - Tedders 
SH, Tedders SH. Recommendations and administration of the HPV vaccine to 11- to 12-
year-old girls and boys: a statewide survey of Georgia vaccines for children provider 
practices. (1526-0976 (Electronic)). 
76. Malo TL, Hassani D, Staras SA, Shenkman EA, Giuliano AR, Vadaparampil ST. Do Florida 
Medicaid providers' barriers to HPV vaccination vary based on VFC program participation? 
Maternal and child health journal. 2013;17(4):609-615. 
77. National Vaccine Advisory Committee. Protecting the public's health: critical functions of 
the Section 317 Immunization Program-a report of the National Vaccine Advisory 
Committee. Public health reports (Washington, DC : 1974). 2013;128(2):78-95. 
78. Henry KA, Swiecki-Sikora AL, Stroup AM, Warner EL, Kepka D. Area-based 
socioeconomic factors and Human Papillomavirus (HPV) vaccination among teen boys in the 
United States. BMC Public Health. 2017;18(1):19. 
 
121 
79. Finney Rutten LJ, Wilson PM, Jacobson DJ, et al. A Population-Based Study of 
Sociodemographic and Geographic Variation in HPV Vaccination. Cancer Epidemiol 
Biomarkers Prev. 2017;26(4):533-540. 
80. Swiecki-Sikora AL, Henry KA, Kepka D. HPV Vaccination Coverage Among US Teens 
Across the Rural-Urban Continuum. The Journal of rural health : official journal of the 
American Rural Health Association and the National Rural Health Care Association. 
2019;35(4):506-517. 
81. Williams CL, Walker TY, Elam-Evans LD, et al. Factors associated with not receiving HPV 
vaccine among adolescents by metropolitan statistical area status, United States, National 
Immunization Survey-Teen, 2016-2017. Hum Vaccin Immunother. 2020;16(3):562-572. 
82. Rahman M, Laz TH, Berenson AB. Geographic variation in human papillomavirus 
vaccination uptake among young adult women in the United States during 2008-2010. 
Vaccine. 2013;31(47):5495-5499. 
83. Sriram S. Why human papilloma virus vaccination coverage is low among adolescents in the 
US? A study of barriers for vaccination uptake. Journal of family medicine and primary 
care.8(3). 
84. Bednarczyk RA, Ellingson MK, Omer SB. Human Papillomavirus vaccination before 13 and 
15 years of age: Analysis of National Immunization Survey Teen data. The Journal of 
infectious diseases. 2019. 
85. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a 
review of the literature. Hum Vaccin Immunother. 2019;15(1):146-155. 
86. Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local 
Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018. 
MMWR Morb Mortal Wkly Rep. 2019;68(33):718-723. 
87. Vadaparampil ST, Kahn JA, Salmon D, et al. Missed clinical opportunities: provider 
recommendations for HPV vaccination for 11–12 year old girls are limited. Vaccine. 
2011;29(47):8634-8641. 
88. Carle AC. Fitting multilevel models in complex survey data with design weights: 
Recommendations. BMC medical research methodology. 2009;9:49. 
89. Roux A-VD. Neighborhoods and health: where are we and were do we go from here? Revue 
d'epidemiologie et de sante publique. 2007;55(1):13-21. 
90. Duncan GJ, Raudenbush SW. Assesing the effects of context in studies of child and youth 
development. Educational Psychologist. 1999;34(1):29-41. 
91. Simon K, Soni A, Cawley J. The Impact of Health Insurance on Preventive Care and Health 
Behaviors: Evidence from the First Two Years of the ACA Medicaid Expansions. Journal of 
 
122 
policy analysis and management : [the journal of the Association for Public Policy Analysis 
and Management]. 2017;36(2):390-417. 
92. Lake PW, Kasting ML, Christy SM, Vadaparampil ST. Provider perspectives on multilevel 
barriers to HPV vaccination. Hum Vaccin Immunother. 2019;15(7-8):1784-1793. 
93. Fu LY, Bonhomme LA, Cooper SC, Joseph JG, Zimet GD. Educational interventions to 
increase HPV vaccination acceptance: a systematic review. Vaccine. 2014;32(17):1901-1920. 
94. Walling EB, Benzoni N, Dornfeld J, et al. Interventions to Improve HPV Vaccine Uptake: A 
Systematic Review. Pediatrics. 2016;138(1):e20153863. 
95. Opel DJ, Mangione-Smith R, Robinson JD, et al. The Influence of Provider Communication 
Behaviors on Parental Vaccine Acceptance and Visit Experience. Am J Public Health. 
2015;105(10):1998-2004. 
96. Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine discussions 
at health supervision visits. Pediatrics. 2013;132(6):1037-1046. 
97. Dang JHT, Stewart SL, Blumberg DA, Rodriguez HP, Chen MS, Jr. "There's Always Next 
Year": Primary Care Team and Parent Perspectives on the Human Papillomavirus Vaccine. 
Hum Vaccin Immunother. 2020;16(8):1814-1823. 
98. Henrikson NB, Tuzzio L, Gilkey MB, McRee AL. "You're never really off time": Healthcare 
providers' interpretations of optimal timing for HPV vaccination. Prev Med Rep. 2016;4:94-
97. 
99. Brehm SS, Brehm JW. Psychological reactance: A theory of freedom and control. Academic 
Press; 2013. 
100. Dempsey AF, Pyrznawoski J, Lockhart S, et al. Effect of a health care professional 
communication training intervention on adolescent human papillomavirus vaccination: a cluster 
randomized clinical trial. JAMA Pediatr. 2018;172(5):e180016-e180016. 
101. Edwards KM, Hackell JM, Diseases CoI, Practice Co, Medicine A. Countering vaccine 
hesitancy. Pediatrics. 2016;138(3). 
102. Hough-Telford C, Kimberlin DW, Aban I, et al. Vaccine delays, refusals, and patient 
dismissals: a survey of pediatricians. Pediatrics. 2016;138(3). 
103. Hughes CC, Jones AL, Feemster KA, Fiks AG. HPV vaccine decision making in pediatric 
primary care: a semi-structured interview study. BMC pediatrics. 2011;11(1):1-9. 
104. Kharbanda EO, Stockwell MS, Fox HW, Andres R, Lara M, Rickert VI. Text message 
reminders to promote human papillomavirus vaccination. Vaccine. 2011;29(14):2537-2541. 
 
123 
105. Matheson EC, Derouin A, Gagliano M, Thompson JA, Blood-Siegfried J. Increasing HPV 
vaccination series completion rates via text message reminders. Journal of Pediatric Health 
Care. 2014;28(4):e35-e39. 
106. Szilagyi PG, Albertin C, Humiston SG, et al. A randomized trial of the effect of centralized 
reminder/recall on immunizations and preventive care visits for adolescents. Academic 
pediatrics. 2013;13(3):204-213. 
107. Ojha RP, Tota JE, Offutt-Powell TN, Klosky JL, Ashokkumar R, Gurney JG. The accuracy 
of human papillomavirus vaccination status based on adult proxy recall or household 
immunization records for adolescent females in the United States: results from the National 
Immunization Survey-Teen. Annals of epidemiology. 2013;23(5):281-285. 
108. Bruno DM, Wilson TE, Gany F, Aragones A. Identifying human papillomavirus 
vaccination practices among primary care providers of minority, low-income and immigrant 
patient populations. Vaccine. 2014;32(33):4149-4154. 
109. Tom A, Robinett H, Buenconsejo-Lum L, et al. Promoting and providing HPV vaccination 
in Hawaii: barriers faced by health providers. Journal of community health. 2016;41(5):1069-
1077. 
110. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to Human 
Papillomavirus Vaccination Among US Adolescents. JAMA Pediatr. 2014;168(1):76-82. 
111. Do EK, Rossi B, Miller CA, et al. Area-Level Variation and Human Papillomavirus 
Vaccination among Adolescents and Young Adults in the United States: A Systematic Review. 
Cancer Epidemiol Biomarkers Prev. 2021;30(1):13-21. 
112. Centers for Disease Control and Prevention. IQIP At A Glance. 2020; 
https://www.cdc.gov/vaccines/programs/iqip/at-a-glance.html. Accessed April 26, 2020. 
113. Shah PD, Calo WA, Gilkey MB, et al. Questions and Concerns About HPV Vaccine: A 
Communication Experiment. Pediatrics. 2019;143(2). 
 
